Osiris Therapeutics 10-K 20 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 06, 2015	Jun. 28, 2013
Document and Entity Information
Entity Registrant Name	OSIRIS THERAPEUTICS, INC.
Entity Central Index Key	1360886
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$535,919,076
Entity Common Stock, Shares Outstanding		34,352,063
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash	$2,208	$2,416
Investments available for sale	37,305	39,508
Trading securities	10,591	17,086
Trade accounts receivable, net of reserves	24,307	7,459
Other receivables	9,951	15,265
Inventory	10,924	1,929
Prepaid expenses and other current assets	650	355
Current assets of discontinued operations		91
Total current assets	95,936	84,109
Property and equipment, net	2,087	1,896
Deferred tax asset		5,849
Other assets	95
Restricted cash		243
Total assets	98,118	92,097
Current liabilities:
Accounts payable and accrued expenses	8,854	4,842
Capital lease obligations, current portion	45	45
Deferred commissions payable, current portion	1,667
Deferred tax liability		5,849
Current liabilities of discontinued operations		57
Total current liabilities	10,566	10,793
Other long-term liabilities	3,589	355
Total liabilities	14,155	11,148
Commitments and contingencies
Stockholders' equity
Common stock, $.001 par value, 90,000 shares authorized, 34,346 shares outstanding - 2014, 34,115 shares outstanding - 2013	35	34
Additional paid-in-capital	287,525	282,702
Accumulated other comprehensive loss	-54	-33
Accumulated deficit	-203,543	-201,754
Total stockholders' equity	83,963	80,949
Total liabilities and stockholders' equity	$98,118	$92,097

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
CONDENSED BALANCE SHEETS
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	90,000	90,000
Common stock, shares outstanding	34,346	34,115

STATEMENTS_OF_COMPREHENSIVE_LO

STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
STATEMENTS OF COMPREHENSIVE LOSS
Product revenues	$59,867	$24,308	$7,849
Cost of product revenues	13,171	6,656	2,551
Gross profit	46,696	17,652	5,298
Operating expenses:
Research and development	6,862	4,952	5,501
Selling, general and administrative	37,432	15,291	3,676
Fees paid to related parties	281	62	36
Share based payments to related parties	403	180	1,918
Total operating expenses	44,978	20,485	11,131
Income (loss) from operations	1,718	-2,833	-5,833
Other Nonoperating Income (Expense)	-1,771	414	49
Loss from continuing operations, before income taxes	-53	-2,419	-5,784
Income tax benefit	-193	1,326	37
(Loss) from continuing operations	-246	-1,093	-5,747
Discontinued operations:
Loss from operations of discontinued operations, net of income taxes of $941 in 2014 $0 in 2013, and $0 in 2012	1,543	6,668	5,318
Gain from sale of discontinued operations, net of income taxes of $1,705 in 2013		49,399
(Loss) income from discontinued operations	-1,543	42,731	-5,318
Net (loss) income	-1,789	41,638	-11,065
Other comprehensive income (loss)
Unrealized (loss) on investments available for sale	-21	-13	-40
Comprehensive (loss) income	($1,810)	$41,625	($11,105)
Basic and diluted (loss) income per share
Income (loss) from continuing operations (in dollars per share)	($0.01)	($0.04)	($0.17)
Income (loss) from discontinued operations (in dollars per share)	($0.04)	$1.29	($0.16)
Basic and diluted income (loss) per share (in dollars per share)	($0.05)	$1.25	($0.33)
Weighted average common shares (basic and diluted) (in shares)	34,263	33,307	32,859

STATEMENTS_OF_COMPREHENSIVE_LO1

STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
STATEMENTS OF COMPREHENSIVE LOSS
Income tax expense, which was offset against the income from discontinued operations	$941	$0	$0
Gain from sale of discontinued operations, income taxes		1,705
Income tax expense	($941)	$0	$0

STATEMENTS_OF_CHANGES_IN_STOCK

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	Total
Balance at Dec. 31, 2011	$33,000	$278,092,000	$20,000	($232,327,000)	$45,818,000
Balance (in shares) at Dec. 31, 2011	32,827,521
Increase (Decrease) in Stockholders' Equity
Exercise of options to purchase common stock ($.40- $22.74 per share)		87,000			87,000
Exercise of options to purchase common stock (in shares)	28,708
Share-based payment-director services ($0.00, $7.73, and $5.08 per share) for 2014, 2013 and 2012, respectively		127,000			127,000
Share-based payment-director services (in shares)	25,000
Share-based payment-employee compensation		963,000			963,000
Net (loss) income				-11,065,000	-11,065,000
Unrealized gain (loss) on investments available for sale			-40,000		-40,000
Balance at Dec. 31, 2012	33,000	279,269,000	-20,000	-243,392,000	35,890,000
Balance (in shares) at Dec. 31, 2012	32,881,229
Increase (Decrease) in Stockholders' Equity
Exercise of options to purchase common stock ($.40- $22.74 per share)		2,193,000			2,193,000
Exercise of options to purchase common stock (in shares)	642,514
Share-based payment-director services ($0.00, $7.73, and $5.08 per share) for 2014, 2013 and 2012, respectively		180,000			180,000
Share-based payment-director services (in shares)	23,250
Net exercise of warrant to purchase common stock ($00.00 and $11.00 per share) in 2014 and 2013, respectively	1,000	-1,000
Net exercise of warrant to purchase common stock (in shares)	567,610
Share-based payment-employee compensation		1,061,000			1,061,000
Net (loss) income				41,638,000	41,638,000
Unrealized gain (loss) on investments available for sale			-13,000		-13,000
Balance at Dec. 31, 2013	34,000	282,702,000	-33,000	-201,754,000	80,949,000
Balance (in shares) at Dec. 31, 2013	34,114,603				34,115,000
Increase (Decrease) in Stockholders' Equity
Exercise of options to purchase common stock ($.40- $22.74 per share)	1,000	1,684,000			1,685,000
Exercise of options to purchase common stock (in shares)	204,085
Share-based payment-director services ($0.00, $7.73, and $5.08 per share) for 2014, 2013 and 2012, respectively		403,000			403,000
Share-based payment-director services (in shares)	27,000
Share-based payment-employee compensation		2,729,000			2,729,000
Net (loss) income				-1,789,000	-1,789,000
Unrealized gain (loss) on investments available for sale			-21,000		-21,000
Windfall tax benefit from stock-based compensation		7,000			7,000
Balance at Dec. 31, 2014	$35,000	$287,525,000	($54,000)	($203,543,000)	$83,963,000
Balance (in shares) at Dec. 31, 2014	34,345,688				34,346,000

STATEMENTS_OF_CHANGES_IN_STOCK1

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
Exercise of options to purchase common stock, per share, low end of range	$0.40	$0.40	$0.40
Exercise of options to purchase common stock, per share, high end of range	$14.19	$22.74	$7.74
Share-based payment-director services, per share	$14.93	$7.73	$5.08
Exercise of warrant to purchase common stock, per share		$11

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Continuing operations
(Loss) income from continuing operations	($246)	($1,093)	($5,747)
Adjustments to reconcile loss from continuing operations to net cash used in operations of continuing operations:
Unrealized loss on trading securities	401	-401
Depreciation and amortization	940	587	552
Non cash share-based payments	3,132	583	492
Provision for bad debts	1,178	80	22
Changes in operating assets and liabilities:
Accounts receivable	-18,026	-4,685	-2,185
Inventory	-8,995	-651	-511
Prepaid expenses, and other current assets	-572	158	-259
Tax Receivable		-160	2,188
Other assets	-95
Accounts payable, accrued expenses, and other current liabilities	3,958	2,605	665
Net cash used in operating activities of continuing operations	-18,325	-2,977	-4,783
Discontinued operations
Loss from discontinued operations	1,543	6,668	5,318
Adjustments to reconcile loss from discontinued operations to net cash used in operations of discontinued operations:
Non cash impact of the sale of discontinued operations	1,685	-1,705
Depreciation and amortization		156	156
Non cash share-based payments		658	598
Changes in operating assets and liabilities:
Accounts receivable and other current assets	15,091	113	-172
Accounts payable and accrued expenses	-57	-2,846	-419
Deferred revenue			-3,333
Net cash provided by (used in) operations of discontinued operations	15,176	-10,292	-8,488
Net cash used in operating activities	-3,149	-13,269	-13,271
Cash flows from investing activities:
Purchases of property and equipment	-1,131	-528	-128
Proceeds from sale of discontinued operations, net		19,419
Proceeds from sale of investments available for sale	114,374	55,357	217,185
Purchases of investments available for sale	-112,192	-62,640	-203,733
Net cash provided by investing activities	1,051	11,608	13,324
Cash flows from financing activities:
Principal payments on capital lease obligations	-45	-44	-22
Restricted cash	243	74	75
Proceeds from the exercise of options to purchase common stock	1,685	2,193	87
Windfall benefit from stock-based compensation	7
Net cash provided by financing activities	1,890	2,223	140
Net increase (decrease) in cash	-208	562	193
Cash at beginning of period	2,416	1,854	1,661
Cash at end of period	2,208	2,416	1,854
Supplemental disclosure of cash flows information:
Cash paid for income taxes	619	539
Supplemental disclosure of non cash activities:
Deferred compensation related to Stryker agreement	5,000
Equipment acquired under a capital lease			228
Guaranteed payment related to trading securities	4,409
Trading securities from the sales of discontinued operations		15,000
Purchase price guarantee related to trading securities	-1,685	1,685
Proceeds receivable due from sale of discontinued operations		15,000
Unrealized loss on investments available for sale	$21	$13	$40

Description_of_Business_and_Si

Description of Business and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Description of Business and Significant Accounting Policies
Description of Business and Significant Accounting Policies
	1. Description of Business and Significant Accounting Policies
	Description of Business
	Osiris Therapeutics, Inc. ("we," "us," "our," or the "Company") is a Maryland corporation headquartered in Columbia, Maryland. We began operations on December 23, 1992 and were a Delaware corporation until, with approval of our stockholders, we reincorporated as a Maryland corporation on May 31, 2010. We are a world leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs. We continue to advance research and development in biotechnology by focusing on innovation in regenerative medicine, including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopedics, sports medicine and wound care.
	From 2010 to 2013, we operated our business in two segments, Biosurgery and Therapeutics. Our Biosurgery business focuses on products for wound healing, cartilage repair, and orthopedics to harness the ability of cells and novel constructs to promote the body's natural healing. Our Therapeutics business focused on developing biologic stem cell drug candidates from a readily available and non-controversial source—adult bone marrow—until it was sold, as described further below.
	Our Biosurgery business has continued to grow since its inception, and we have increased our organizational focus on the development and commercialization of products in this segment. Consistent with this organizational focus, as discussed further in Note 2—Discontinued Operations below, on October 10, 2013, we entered into a Purchase Agreement to sell our Therapeutics segment, including all of our culture expanded mesenchymal stem cell business, including Prochymal and other related assets. We eliminated the Therapeutics segment from our continuing operations as a result of the disposal transaction, and have presented the assets, liabilities, and results of the segment's operations as a discontinued operation for all periods presented. Our continuing operations now represent the portion of our business previously referred to as our Biosurgery segment.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Due to the inherent uncertainty involved in making those assumptions, actual results could differ from those estimates. We believe that the most significant estimates that affect our financial statements are those that relate to deferred tax assets, inventory valuation, share-based compensation and the value of the derivative obtained in connection with the sale of our former Therapeutics business.
	Cash and Cash Equivalents
	Amounts listed as cash on our balance sheets are maintained in depository accounts at a commercial bank. Cash and cash equivalents, which include highly liquid investments with maturities of three months or less when purchased, held in our brokerage investment accounts are classified as investments available for sale, as the amounts represent investments that have matured and are anticipated to be reinvested in debt securities in the near future, and are disclosed at fair value, which approximates cost.
	Reclassifications
	We have reclassified certain prior-year amounts for comparative purposes. These reclassifications did not affect our results of operations or financial positions for the years presented.
	Investments Available for Sale
	Investments available for sale consist primarily of marketable securities with maturities less than one year. Investments available for sale are valued at their fair value, with unrealized gains and losses reported as a separate component of stockholders' equity in accumulated other comprehensive income. All realized gains and losses on our investments available for sale are recognized in results of operations as other income.
	Investments available for sale are evaluated periodically to determine whether a decline in their value is "other than temporary." The term "other than temporary" is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. We review criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. If a decline in value is determined to be other than temporary, the carrying value of the security is reduced and a corresponding charge to earnings is recognized.
	Restricted Cash
	We periodically are required under the terms of various agreements to provide letters of credit which are collateralized by cash deposits. The majority of the restricted cash balance relates to a letter of credit that we caused to be issued in lieu of a security deposit under the operating lease for our Columbia, Maryland facility.
	Trade Accounts Receivable
	Trade accounts receivable are reported at their net realizable value. We charge off uncollectible receivables when the likelihood of collection is remote. We set credit terms with individual customers, and consider receivables outstanding longer than the time specified in the respective customer's contract, typically 45-days, to be past due. As of December 31, 2014 and 2013, accounts receivable in the accompanying balance sheets are reported net of a $1,256,000 and a $78,000 allowance for doubtful accounts, respectively. We believe the reported amounts are fully collectible. Trade accounts receivable balances are not collateralized. We have incurred bad debt expense of $1,178,000, $80,000 and $22,000 related to our Biosurgery operations during fiscal 2014, 2013 and 2012, respectively.
	Inventory
	We began carrying inventory of our Biosurgery products on our balance sheet following commercial launch of such products. Inventory consists of raw materials, biologic products in process, and products available for distribution. We determine our inventory values using the first-in, first-out method. Inventory is valued at the lower of cost or market, and excludes units that we anticipate distributing for clinical evaluation.
	Property and Equipment
	Property and equipment, including improvements that extend useful lives, are valued at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on estimated useful lives ranging from three to seven years for furniture, equipment and internal use software. Leasehold improvements and assets under capital leases are amortized over the shorter of the estimated useful life of the asset or the original term of the lease.
	Valuation of Long-lived Assets
	We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, we evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. There were no impairment losses recognized during fiscal years 2014, 2013 or 2012.
	Derivative and Securities Received in Business Disposition
	As discussed in Note 2—Discontinued Operations, we disposed of our Therapeutics segment in October 2013. A portion of the consideration for the sale of that business was stock of Mesoblast Limited ("Mesoblast"), the parent of the purchaser. We were required to hold that stock for one year from the date of receipt. We intended to dispose of the Mesoblast stock as soon as we were able to do so. Mesoblast is a public company and its stock is traded on the Australian stock exchange. As of December 31, 2014 and 2013, we reflect the investment as a current asset in Trading Securities. In December 2014, the price protection on these shares expired, but Mesoblast agreed to pay us $15 million in cash for the stock in the first half of fiscal 2015. Accordingly, as of December 31, 2014, this $15 million is shown as $10.6 million in Trading Securities and $4.4 million in Other Receivables on our Balance Sheets.
	The Mesoblast stock was previously subject to limited price protection for the one year required holding period. To the extent the value of those shares decreased during the holding period, Mesoblast was required to pay us for the decrease in value. This payment was to be made at least one half in cash and at the option of Mesoblast, up to one half in additional shares of Mesoblast stock. Any additional Mesoblast stock would also have to be held for one year during which period there was no further price protection. In fiscal 2013, the price protection was accounted for as a derivative under ASC 815, Derivatives and Hedging, and, as such was recorded on the balance sheets at fair value, with changes recognized in net income. We elected to measure the Mesoblast stock at fair value with changes in fair value reflected in net income, as permitted under ASC 825-10, Financial Instruments—Fair Value Option. The price protection ended in December 2014 and we no longer have a derivative instrument.
	All derivative instruments within the scope of ASC 815, Derivatives and Hedging, are recorded on the balance sheet at fair value. As of December 31, 2013 our only derivative instrument was the price guarantee regarding the payment received in restricted Mesoblast shares described in Note 13—Derivative and Securities Received in Business Disposition below. We do not hold derivative financial instruments for trading purposes.
	Biosurgery Revenue Recognition
	We recognize revenue from product distribution when title passes to the customer. Title usually passes when the product is shipped to the customer and leaves our loading dock. In some situations, we store consigned inventory on site in freezers at hospital or clinic facilities. No revenue is recognized upon the placement of inventory into consignment as we retain title and maintain the inventory on our balance sheet. For these products, revenue is recognized when we receive appropriate notification that the product has been used in a surgical procedure. We verify the condition and status of all consigned inventory on at least a quarterly basis. Due to the nature of our products and the need to ensure they are maintained at the proper frozen temperature, we generally do not allow product returns.
	In December 2014, we entered into exclusive distribution agreements with a subsidiary of Stryker Corporation for the marketing and distribution of BIO4, our viable bone matrix allograft. Pursuant to the agreement, Stryker has been granted worldwide distribution rights to the product and any improvements, for all surgical applications. We will be responsible for supply, manufacturing, inventory management, shipments to customers, continued research and product improvement activities. We will recognize as revenue the amounts charged to customers for the allografts and related services. Commissions and administrative fees paid to Stryker will be accounted for as selling expenses, as Stryker is acting as outside sales and marketing agent for Osiris. We are entitled to receive an initial exclusivity fee of $5.0 million and additional fees upon any exercise by Stryker of its right to extend the initial term, whether on an exclusive or non-exclusive basis. The exclusivity fee and any extension fees subsequently received are considered to be adjustments of the selling expenses. As such, we recognize the exclusively fee as a liability and will be amortized over the related exclusivity period in proportion to the expected fees to be paid to Stryker, as an offset to selling expenses. At December 31, 2014, Osiris recorded a $5.0 million receivable included in other receivables with the offset to short-term deferred commissions of $1.67 million and long-term deferred commissions $3.33 million included in other long term liabilities.
	In October 2014, we entered into an exclusive commercial and development partnership for our cartilage product, Cartiform, with Arthrex, Inc. The agreement provides Arthrex with exclusive commercial distribution rights to Cartiform beginning in 2015. We will be responsible for manufacturing, continued research and product improvement activities. The responsibilities related to the design and conduct of future clinical development programs will be shared between both organizations. Pursuant to the agreement, Arthrex is entitled to a certain commission on Cartiform sales. We will recognize the full sales price as revenue and account for the payment to Arthrex as commission expense.
	Therapeutics Revenue Recognition
	In our former Therapeutics business, we evaluated revenues from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting. To recognize a delivered item in a multiple element arrangement, the delivered items must have value on a standalone basis and the delivery or performance must be probable and within our control for any delivered items that have a right of return. The determination of whether multiple elements of a collaboration agreement meet the criteria for separate units of accounting requires us to exercise judgment. We account for the activities of our former Therapeutics business as discontinued operations.
	Revenues from research licenses associated with our former Therapeutics business were recognized as earned upon either the incurring of reimbursable expenses directly related to the particular research plan or the completion of certain development milestones as defined within the terms of the agreement. Payments received in advance of research performance were designated as deferred revenue. Non-refundable upfront license fees and certain other related fees associated with our former Therapeutics business were recognized on a straight-line basis over the development periods of the contract deliverables. Fees associated with substantive at risk performance based milestones are recognized as revenue upon their completion, as defined in the respective agreements. Incidental assignment of technology rights were recognized as revenue when and if it was earned and received.
	In October 2008, we entered into a Collaboration Agreement with Genzyme Corporation, then an independent and now a Sanofi company ("Genzyme"), for the development and commercialization of our biologic drug candidates, Prochymal and Chondrogen™. Under this agreement, Genzyme made non-contingent, non-refundable cash payments to us, totaling $130 million. The agreement provided Genzyme with certain rights to intellectual property developed by us, and required that we continue to perform certain development work related to the subject biologic drug candidates. In February 2012, Sanofi issued a press release which included an update on their R&D pipeline, stating that it had discontinued its project with Prochymal for GvHD. In September 2012, we reached agreement with Sanofi to conclude the Collaboration Agreement without either party having any continuing obligation to the other.
	We evaluated the deliverables related to the upfront payments made to us under the Genzyme collaboration agreement, and concluded that the various deliverables represent a single unit of accounting. For this reason, we deferred the recognition of revenue related to the upfront payments, and amortized these amounts to revenue on a straight-line basis over the estimated delivery period of the required development services, which extended through January 2012.
	Research and Development Costs
	We expense internal and external research and development ("R&D") costs, including costs of funded R&D arrangements and the manufacture of clinical batches of Biosurgery products used in clinical trials, in the period incurred.
	Internal resources are applied interchangeably across several product candidates due to the potential applicability of our biologic drug candidates for multiple indications.
	Income Taxes
	Deferred tax liabilities and assets are recognized for the estimated future tax consequences of temporary differences, income tax credits and net operating loss carry-forwards. Temporary differences are primarily the result of the differences between the tax bases of assets and liabilities and their financial reporting values. Deferred tax liabilities and assets are measured by applying the enacted statutory tax rates applicable to the future years in which deferred tax liabilities or assets are expected to be settled or realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense, if any, consists of the taxes payable for the current period and the change during the period in deferred tax assets and liabilities.
	We recognize in our financial statements the impact of a tax position, if that position is more likely than not to be sustained upon an examination, based on the technical merits of the position. Interest and penalties related to income tax matters are recorded as income tax expense. At December 31, 2014 and 2013, we had no accruals for interest or penalties related to income tax matters.
	Income per Common Share
	Basic income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted income per common share adjusts basic income per share for the potentially dilutive effects of common share equivalents, using the treasury stock method, and includes the incremental effect of shares that would be issued upon the assumed exercise of stock options and warrants.
	Diluted loss from continuing operations for the year ended December 31, 2014 excluded all 1,608,557 shares issuable upon the exercise of options, as their impact on our loss from continuing operations is anti-dilutive. As a result, basic and diluted weighted average common shares outstanding are identical.
	Diluted loss from continuing operations for the year ended December 31, 2013 excluded all 1,233,767 shares issuable upon the exercise of options, as their impact on our loss from continuing operations is anti-dilutive. As a result, basic and diluted weighted average common shares outstanding are identical.
	Diluted loss per common share for the year ended December 31, 2012 excludes the 1,000,000 shares issuable upon the exercise of an outstanding "out-of the money" warrant, and all 1,826,114 of our outstanding options as of December 31, 2012, as their impact on our net loss is anti-dilutive. As a result, basic and diluted weighted average common shares outstanding are identical.
	Share-Based Compensation
	We account for share-based payments using the fair value method.
	We recognize all share-based payments to employees and non-employee directors in our financial statements based on their grant date fair values, calculated using the Black-Scholes option pricing model. Compensation expense related to share-based awards is recognized on a straight-line basis for each vesting tranche based on the value of share awards that are expected to vest on the grant date, which is revised if actual forfeitures differ materially from original expectations.
	Comprehensive Income
	Comprehensive income consists of net income and all changes in equity from non-stockholder sources, which consist of changes in unrealized gains and losses on investments.
	Concentration of Risk
	We maintain cash and short-term investment balances in accounts that exceed federally insured limits, although we have not experienced any losses on such accounts. We also invest excess cash in investment grade securities, generally with maturities of one year or less.
	We have historically provided credit in the normal course of business to contract counterparties and to the distributors of our product. Trade accounts receivable in the accompanying balance sheets consist primarily of amounts due from distributors of our Biosurgery products within the United States. During fiscal 2014 and 2013 respectively, revenues from one of the distributors of our Biosurgery products, Stability Biologics, comprised approximately 10% and 50% of our total Biosurgery revenues. As of December 31, 2014 and 2013 respectively, receivables from this distributor comprised 13% and 6% of our total receivables. As discussed under "Trade Accounts Receivable" above, we have incurred bad debt expense of $1,178,000, $80,000 and $22,000 for the three years ended December 31, 2014, 2013 and 2012, respectively.
	Recent Accounting Guidance Not Yet Adopted at December 31, 2014
	In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers," which requires an entity to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application. We are currently assessing the impact the adoption of ASU 2014-09 will have on our financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements—Going Concern," which require management to evaluate, at each reporting period, whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently assessing the impact the adoption of ASU 2014-15 will have on our financial statements.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2014
Discontinued Operations
Discontinued Operations	2. Discontinued Operations
	As reported on our Current Report on Form 8-K, dated October 10, 2013, we entered into a Purchase Agreement with Mesoblast, pursuant to the terms of which we sold our culture expanded mesenchymal stem cell (ceMSC) business, including Prochymal and other related assets. The Purchase Agreement provides for payment to us of $50 million in initial consideration, and payment of up to an additional $50 million upon the achievement by Mesoblast of certain clinical and regulatory milestones. Additionally, we will be entitled to earn low single to double digit cash royalties on future sales by Mesoblast of Prochymal and other products utilizing the acquired ceMSC technology.
	The Purchase Agreement provides for the $50.0 million of initial payments and up to $50.0 million of contingent additional payments to us upon our achievement of milestone events, as follows:
	Milestone	Amount
		$0
	Initial consideration
	Letter of intent payments	$	3,500
	Initial closing payment		16,500
	Additional closing payment, 6 months after closing date		15,000
	Delivery of all scheduled assets under the Transfer Agreement		15,000
	Total initial consideration		50,000
	Contingent onsideration
	First marketing authorization received in the U.S.		20,000
	First marketing authorization received from France, Germany, or European Union		10,000
	Completion of the enrollment of the Phase 3 Crohn's Trial or Mesoblast's election to discontinue the trial		10,000
	Receipt of final data for the Crohn's trial or first marketing approval for Crohn's		10,000
	Total conditional consideration		50,000
	Total possible purchase price	$	100,000
	Of the $50 million in total initial consideration, we received at December 31, 2013, payment of $20 million in cash, and $15 million in Mesoblast ordinary shares, which were delivered to us upon completed delivery of the ceMSC assets. The remaining $15 million of the initial consideration was paid in cash in April 2014. The Mesoblast shares received by us were subject to a one year holding period from the date of receipt, but had limited downside protection for a drop in the Mesoblast share price over the holding period. We evaluated this downside protection, and determined that it met the criteria of a derivative instrument. The fair value of the protection at the time of the disposition of our Therapeutics business was $1.7 million. We recognized the price protection derivative as an asset at December 31, 2013 at its then fair value of $1.7 million, which was reflected in the calculation of the gain on sale of the Therapeutics business. The price protection ended in December 2014 and Mesoblast agreed to pay us no less than $15 million in cash for the stock prior to the end of the first half of fiscal 2015. Accordingly, we no longer have a derivative instrument as of December 31, 2014.
	Our ability to receive the second $50 million is subject to satisfaction of the milestones indicated above all of which are largely dependent upon the clinical and regulatory success of Mesoblast and other factors not in our control. These include many if not all of the risks and uncertainties that our ceMSC business was subject to prior to its sale to Mesoblast, including product development, efficacy and regulatory risks. We have received no such payments thus far, nor do we have any expectation of receiving any such payments in the foreseeable future. Our ability to earn royalties from Mesoblast is subject to these same risks and will require performance by Mesoblast that results in its meeting some or all of the milestones referred to above, and is thereafter also dependent upon the commercial success of Mesoblast's ceMSC business. Royalties, if any, are payable to us in cash. Any portion of the second $50 million that becomes payable to us will be payable, at the discretion of Mesoblast, in Mesoblast ordinary shares, based on a then current valuation of such shares. Any such Mesoblast ordinary shares that we receive will also be subject to a one year holding period, with the same limited downside protection described above.
	We eliminated the Therapeutics segment from our continuing operations as a result of the disposal transaction and have presented the assets, liabilities, and results of the segment's operations as a discontinued operation for all periods presented. We have no continuing involvement with the Therapeutics business, and the only continuing cash flows to us related to the Therapeutics business will be the contingent consideration and royalties provided for under the purchase agreement, as described above. We received no such contingent payments or royalties in 2014 or 2013.
	We recognized a gain of approximately $49.4 million of the sale of discontinued operations during the year ended December 31, 2013, representing the $50.0 million in initial payments received under the Purchase Agreement and the $1.7 million fair value of the derivative instrument received, net of transaction costs of $0.6 million, including legal, accounting and advisory fees, and income tax expense of $1.7 million.
	The net assets allocable to the Therapeutics business at December 31, 2014 and 2013 were as follows:
		2014			2013
		($000s)			($000s)
	Current assets:
	Accounts receivable	$	—		$	91
	Current liabilities:
	Accounts payable and accrued expenses	$	—		$	57
	Summarized operating results of the Therapeutics segment are as follows:
		Year ended
		December 31, ($000s)
		2014			2013			2012
	Revenue from collaborative research agreements and royalties	$	288		$	639		$	3,955
	Operating expenses:
	Research and development	$	299			6,426			8,607
	Selling, general and administrative		591			881			666
			890			7,307			9,273
	Loss from discontinued operations before income tax expense		(602	)		(6,668	)		(5,318	)
	Income tax expense		(941	)		—			—
	Loss from discontinued operations	$	(1,543	)	$	(6,668	)	$	(5,318	)
	Revenues for our Therapeutics segment historically consisted primarily of collaborative research agreements and royalties. Because of the disposition of our Therapeutics business in 2013, we no longer incur related research and development expenses related to these discontinued operations. Our Therapeutics segment also earned royalty revenues and cost reimbursement under our adult expanded access program. Royalties are earned on the sale of human mesenchymal stem cells sold for research purposes. We recognize this revenue as sales are made. Revenues from our former Therapeutics business include approximately $288,000 of royalty revenue in 2014, $215,000 of royalty revenue in 2013, and $305,000 of royalty revenue in 2012. Revenues from our former Therapeutics business also include approximately $0, $424 000, and $296,000 in cost reimbursement for Prochymal used in our adult expanded access program during 2014, 2013, and 2012, respectively.

Segment_Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2014
Segment Reporting
Segment Reporting
	3. Segment Reporting
	Prior to the sale of our Therapeutics business in 2013, we managed our business in two operating segments: our Biosurgery segment and our Therapeutics segment.
	Our Biosurgery segment is focused on the development, manufacture and distribution of biologic products for wound healing, cartilage repair, and orthopedics to harness the ability of cells and novel constructs to promote the body's natural healing. We launched Grafix for commercial distribution in 2010, began distribution of Ovation in early fiscal 2011, and began distribution of Cartiform during 2013. We transitioned Ovation to OvationOS (now branded as BIO4) during the second half of 2014. We have continued to increase our distribution volume of these products since their respective commercial launches and are developing additional products for future commercialization. We have developed a proprietary direct sales force in the field of wound care for the marketing and distribution of Grafix and have entered into exclusive distribution agreements with a subsidiary of Stryker Corporation for the marketing and distribution of BIO4, and with Arthrex, Inc. for the marketing and distribution of Cartiform.
	Our Therapeutics segment focused on developing and marketing products to treat medical conditions in the inflammatory and cardiovascular disease areas. Its operations have focused on clinical trials and discovery efforts. As disclosed in Note 2—Discontinued Operations, we entered into a Purchase Agreement with Mesoblast, pursuant to the terms of which we sold our culture expanded mesenchymal stem cell business, including Prochymal and other related assets.
	Given the sale of our former Therapeutics segment, we now have only one operating segment in the United States of America. As such, our financial statements present the assets, liabilities, and results of the former Therapeutics segment as discontinued operations for all periods presented, the rest of our balance sheets and statements of comprehensive (loss) income present information of the remaining Biosurgery segment.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property and Equipment
Property and Equipment
	4. Property and Equipment
	Property and equipment at December 31, 2014 and 2013 are as follows:
		2014			2013
		($000s)			($000s)
	Laboratory and manufacturing equipment	$	1,211		$	663
	Computer hardware, furniture and fixtures		1,377			899
	Leased assets		228			228
	Leasehold improvements		4,365			4,260
			7,181			6,050
	Accumulated depreciation and amortization		(5,094	)		(4,154	)
	Property and equipment, net	$	2,087		$	1,896
	Depreciation expense was $940,000, $587,000 and $552,000 for 2014, 2013 and 2012, respectively

Inventory

Inventory	12 Months Ended
	Dec. 31, 2014
Inventory
Inventory	5. Inventory
	We began carrying inventory of our Biosurgery products on our balance sheet following commercial launch of such products.
	As of December 31, 2014 and 2013, inventory for our Biosurgery business consists of the following:
		2014		2013
		($000s)		($000s)
	Inventory
	Raw materials and supplies	$	1,025	$	387
	Work-in-process		465		22
	Finished goods		9,434		1,520
	Total Biosurgery inventory, net		10,924		1,929
	Prior to the transaction described in Note 2—Discontinued Operations, we did not carry any inventory for our Therapeutics products, as we had yet to launch Prochymal for commercial distribution.

Capital_Lease

Capital Lease	12 Months Ended
	Dec. 31, 2014
Capital Lease
Capital Lease
	6. Capital Lease
	In July 2012, we leased equipment under a capital lease at an effective interest rate of approximately 5%, with 60 monthly payments of $4,000 starting July 2012. The capital lease is recorded at the present value of the future minimum lease payments. Future minimum lease payments under the capital lease agreement at December 31, 2014 are as follows:
	December 31,	Amount
		(000s)
	2015	$	48
	2016		48
	2017		24
			120
	Less: Amount representing interest		(3	)
	Present value of minimum lease payments		117
	Less: Current portion of capital lease obligations		(45	)
	Long-term portion of capital lease obligations		72

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2014
Share-Based Compensation
Share-Based Compensation	7. Share-Based Compensation
	In April 2006, we adopted our 2006 Omnibus Plan. We amended and restated this plan in 2008 and 2010, and amended it further in 2012, in each case to, among other things, increase the number of shares available for grant. In addition, we had previously established our Amended and Restated 1994 Stock Incentive Plan. Both Plans authorize the issuance of various forms of stock-based awards, including incentive and non-qualified stock options, stock purchase rights, stock appreciation rights and restricted and unrestricted stock awards. A total of 2,250,000 shares of our common stock have been reserved for issuance under the Amended and Restated 2006 Omnibus Plan, and 736,378 shares were reserved under our Amended and Restated 1994 Stock Incentive Plan. We ceased all grants under the Amended and Restated 1994 Stock Incentive Plan concurrent with our initial public offering in August 2006. As a result, no shares are currently available for future awards under the Amended and Restated 1994 Stock Incentive Plan. At December 31, 2014, there were approximately 513,906 shares available for future awards under the Amended and Restated 2006 Omnibus Plan.
	We generally issue stock option awards that vest over four years and have a ten-year contractual life. We estimate the fair value of stock options using the Black-Scholes option-pricing model. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. The fair value of stock options granted during each of the periods was estimated using the following assumptions:
		Years ended December 31,
		2014			2013			2012
	Assumptions:
	Weighted average risk-free interest rate		1.50	%		1.00-1.50	%		2.00	%
	Dividend yield		0.00	%		0.00	%		0.00	%
	Expected life of option grants		5.0 yrs			5.0-6.5 yrs			6.0-6.3 yrs
	Weighted average expected stock price volatility		60	%		52-61	%		52-54	%
	The expected life of stock options granted was based on the our historical option exercise experience and post vesting forfeiture experience using the historical expected term from the vesting date. The expected volatility of the options granted was determined using historical volatilities based on stock prices over a look-back period corresponding to the expected life. The risk-free interest rate was determined using the yield available for zero-coupon United States government issues with a remaining term approximating the expected life of the options. The forfeiture rate was determined based on historical pre-vesting forfeitures. We have never paid a dividend and have no intention to pay a dividend, and as such, the dividend yield is zero.
	In connection with the stock options exercised during the year ended December 31, 2014, we received cash proceeds of $1.7 million. At December 31, 2014, there was $4.6 million of total unrecognized compensation costs related to non-vested stock options, which is expected to be recognized through fiscal 2018.
	A summary of stock option activity for the years ended December 31, 2014, 2013, and 2012 is as follows:
		Number of			Weighted			Weighted		Aggregate
		Shares			Average			Average		Intrinsic Value
					Exercise			Remaining		(in thousands)
					Price			Contractual Life
	Balance, December 31, 2011		1,702,072		$	9.06		6.8 years
	Granted		302,000		$	5.5
	Exercised		(28,708	)	$	(3.05	)			$	114
	Forfeited or canceled		(149,250	)	$	(7.20	)
	Balance, December 31, 2012		1,826,114		$	8.72		6.1 years		$	4,754
	Granted		452,000		$	9.03
	Exercised		(642,514	)	$	(6.50	)			$	6,983
	Forfeited or canceled		(401,833	)	$	(6.79	)
	Balance, December 31, 2013		1,233,767		$	10.61		6.3 years		$	7,992
	Granted		988,500		$	14.59
	Exercised		(204,085	)	$	8.25				$	1,341
	Forfeited or canceled		(409,625	)	$	15.92
	Balance, December 31, 2014		1,608,557		$	12.01		7.92 years		$	6,774
	Exercisable at December 31, 2014		400,432		$	9.79		5.04 years		$	2,759
	A summary of stock options outstanding at December 31, 2014, by price range is as follows:
		Options Outstanding									Options Exercisable
	Range of	Number			Weighted-Average			Weighted-Average			Number		Weighted-Average
	Exercise Prices	Outstanding			Remaining			Exercise			Outstanding		Exercise Price
					Contractual Life			Price
					(in years)
	$0.40-$4.00		8,813			0.9		$	0.40			8,813	$	0.40
	$4.01-$5.25		133,790			7.1			5.31			51,790		5.08
	$5.26-$7.25		171,815			5.4			6.89			121,065		6.85
	$7.01-$7.75		210,139			7.3			7.73			86,764		7.74
	$7.76-$8.50		6,625			7.9			8.22			750		7.80
	$8.51-$12.75		151,375			7.9			11.42			42,750		11.23
	$12.76-$14.00		342,000			9.4			13.51			8,250		13.00
	$14.01-$16.00		290,000			9.3			15.01			—		—
	$16.01-$17.50		230,500			8.7			16.48			16,750		17.08
	$17.51-$24.00		63,500			3.6			20.03			63,500		20.03
			1,608,557			8.0		$	12.01			400,432	$	9.79
	The weighted fair value of options granted during the years ended December 31, 2014, 2013, and 2012 were $7.62, $4.68 and $2.82, respectively.
	The table below reflects the total share-based compensation expense, including share-based payments to our non-employee directors, but excluding the non cash expense related to the extension of the expiration date of an outstanding warrant as discussed in Note 9 below recognized in our statements of comprehensive (loss) income for the years ended December 31, 2014, 2013, and 2012.
		Year Ended December 31,
		2014			2013			2012
		(000s)			(000s)			(000s)
	Research and development		1,802			335			238
	Selling, general and administrative		1,330			248			254
	Discontinued operations		—			658			598
	Total		3,132			1,241			1,090

Investments_Available_for_Sale

Investments Available for Sale	12 Months Ended
	Dec. 31, 2014
Investments Available for Sale
Investments Available for Sale
	8. Investments Available for Sale
	Investments available for sale consisted of the following as of December 31, 2014 and 2013:
		December 31, 2014											December 31, 2013
		($000s)											($000s)
				Unrealized											Unrealized
		Cost		Gain			Loss			Fair Value			Cost		Gain			Loss			Fair Value
	Cash equivalents:
	Money market funds & certificates of deposit	$	1,043	$	—		$	—		$	1,043		$	655	$	—		$	—		$	655
	Corporate debt securities & commercial paper		12,835		21			(24	)		12,832			6,355		22			(10	)		6,367
			13,878		21			(24	)		13,875			7,010		22			(10	)		7,022
	Investments:
	Municipal securities		12,400		13			(47	)		12,366			12,507		9			(24	)		12,492
	Agency obligations		5,401		12			(28	)		5,385			6,704		5			(35	)		6,674
	Mutual Funds		—		—			—			—			4,076		—			—			4,076
	US & International government agencies		5,680		1			(2	)		5,679			9,244		—			—			9,244
			23,481		26			(77	)		23,430			32,531		14			(59	)		32,486
	Investments available for sale	$	37,359	$	47		$	(101	)	$	37,305		$	39,541	$	36		$	(69	)	$	39,508
	The cash equivalents detailed above represent highly liquid investments with maturities of three months or less when purchased that are held in our brokerage investment accounts. They are classified as investments available for sale as the amounts represent investments that have matured and are anticipated to be reinvested in debt securities in the near future.
	The following tables summarize the securities with unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position, as of December 31, 2014 and 2013:
		Less than 12 Months					12 Months or More						Total
		Fair		Unrealized			Fair			Unrealized			Fair		Unrealized
		Value		Loss			Value			Loss			Value		Loss
	12/31/2014 ($000s)
	Municipal securities	$	1,000	$	(1	)	$	1,032		$	(46	)	$	2,032	$	(47	)
	Agency obligations		3,939		(28	)		—			—			3,939		(28	)
	Corporate debt securities & commercial paper		7,073		(24	)		—			—			7,073		(24	)
	US & International government agencies		2,873		(2	)		—			—			2,873		(2	)
	Total temporarily impaired	$	14,885	$	(55	)	$	1,032		$	(46	)	$	15,917	$	(101	)
		Less than 12 months					More than 12 months						Total
		Fair		Unrealized			Fair			Unrealized			Fair		Unrealized
		Value		Loss			Value			Loss			Value		Loss
	12/13/2013 ($000s)
	Corporate debt securities & commercial paper	$	3,341	$	(10	)	$	—		$	—		$	3,341	$	(10	)
	Municipal securities		4,530		(24	)		—			—			4,530		(24	)
	Agency obligations		3,804		(35	)		—			—			3,804		(35	)
	Total temporarily impaired	$	11,675	$	(69	)	$	—		$	—		$	11,675	$	(69	)
	The following table summarizes maturities of our investments available for sale as of December 31, 2014 and 2013:
		December 31, 2014					December 31, 2013
		($000s)					($000s)
		Cost		Fair Value			Cost			Fair Value
	Maturities:
	Within 3 months	$	3,056	$	3,056		$	12,663		$	12,664
	Between 3-12 months		12,658		12,660			1,624			1,610
	More than 1 year		21,645		21,589			25,254			25,234
	Investments available for sale	$	37,359	$	37,305		$	39,541		$	39,508
	Realized gains (losses) and investment income earned on investments available for sale were $(390,000), $(414,000), and $0, respectively, for the years ended December 31, 2014, 2013, and 2012, and have been included as a component of "Other income, net" in the accompanying financial statements.

Related_Party_Transactions_and

Related Party Transactions and Warrant	12 Months Ended
	Dec. 31, 2014
Related Party Transactions and Warrant
Related Party Transactions and Warrant	9. Related Party Transactions and Warrant
	Peter Friedli.    Peter Friedli, the Chairman of our Board of Directors, or entities with which he is affiliated, have been responsible for procuring since 1993, an aggregate of approximately $270 million in debt and equity financing for us and our predecessor company. Mr. Friedli is the beneficial owner of approximately 43% of our common stock as of December 31, 2014. Of the shares beneficially owned by Mr. Friedli at December 31, 2014, 85,000 shares were received by him as Board compensation since 1996, 12,500 shares were granted in recognition of his fundraising efforts, as discussed below, 567,610 shares were received by him upon his net exercise of a warrant to purchase 1,000,000 shares of our common stock at $11.00 per share, as described below, and the remaining shares were acquired through investment or through purchase from third parties.
	Of the 85,000 shares received by Mr. Friedli as board compensation since 1996, 10,000 shares, then valued at approximately $149,300, were issued to Mr. Friedli in 2014, 10,000 shares, then valued at approximately $77,000, were issued to Mr. Friedli in 2013, and 10,000 shares, then valued at approximately $51,000, were issued to Mr. Friedli in 2012.
	In response to Mr. Friedli's successful efforts in procuring for us accommodations relative to financing transactions that had occurred prior to our initial public offering, we issued to Mr. Friedli in 2006, in connection with and just prior to our initial public offering, a warrant exercisable for up to 1,000,000 shares of our common stock at $11.00 per share, the price for which shares were sold in the initial public offering. This warrant was originally scheduled to expire in May 2011and was extended to expire in fiscal 2015 by a vote of our stockholders at the 2011 Annual Meeting of Stockholders.
	Mr. Friedli exercised this warrant on August 14, 2013 using the Net Exercise Method, resulting in the net issuance of 567,610 shares of our common stock. As of December 31, 2013, we no longer have any outstanding warrants.
	Prolexys Pharmaceuticals, Inc.    During the third quarter of fiscal 2011 we entered into a contract research agreement with Prolexys Pharmaceuticals, Inc. under which we are conducting for Prolexys an early stage clinical trial investigating a novel compound as a product candidate for cancer therapeutics. This contract was filed as an exhibit to and discussed in a Current Report on Form 8-K filed by us with the SEC primarily because of the related nature of the management and ownership of Prolexys with us and our management and with certain of our significant stockholders, and not because our rights or obligations under the contract research agreement with Prolexys are otherwise material to us. We are not incurring any third party costs related to our work with Prolexys and are primarily contributing only the efforts of employees. All third party costs associated with the Prolexys study are paid directly by Prolexys. As of December 31, 2014, the amount of internal resources we have devoted to Prolexys is not material to our operations as a whole.
	Prolexys is 35.7% owned by BIH SA, which owns 7.8% of our outstanding common stock; 24.3% owned by Peter Friedli who is the Chairman of our Board of Directors and direct owner of 29.3% of our common stock; and 13.8% owned by Venturetec, Inc., which holds 12.5% of our common stock. Peter Friedli is the President and an approximately 2% owner of Venturetec, Inc. Mr. Friedli has also recently reported the acquisition of a convertible bond that would entitle him, upon conversion, to acquire an additional approximately 19% interest in Venturetec, Inc. Lode Debrabandere, our Chief Executive Officer, serves on the Board of Directors of Prolexys, but has no other interest therein.
	This arrangement is part of our ongoing efforts to expand our portfolio of product candidates, but we do not consider this arrangement to be material to us at this time.
	Our Board of Directors and Audit Committee, including all of our independent directors, but with Mr. Friedli abstaining, unanimously approved this transaction.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes
Income Taxes
	10. Income Taxes
	For income tax reporting purposes, we reported taxable income in fiscal 2014 and 2013, compared to a loss in fiscal 2012. The income in 2014 and 2013 was primarily attributable to the gain from sale of discontinued operations which are reflected in the statements of comprehensive (loss) income, net of income taxes. Continuing operations below reflect a tax expense in the amount of $193,000 and a benefit in the amount of $1.3 million generated during fiscal 2014 and 2013, respectively. Included in the 2013 amount is $79,000 of taxes recoverable from a prior period.
	Included as a component of discontinued operations was a tax expense of $0.9 million and $1.7 million for 2014 and 2013, respectively. The gain from sale of discontinued operations in 2013 included interest to be accrued in the amount of $70,000 which increased income taxes payable. In the future, the utilization of our tax attributes will be limited to the federal alternative minimum tax threshold.
	The effective tax rate benefit (expense) varies from the U.S. Federal Statutory tax rate principally due to the following:
		2014			2013			2012
	U.S. Federal Statutory tax rate		35	%		35	%		35	%
	State taxes, net of federal benefits		(306.6	)		7			—
	Nondeductible expenses		(329.2	)		(1.4	)		(5.6	)
	Stock compensation		(2,762.8	)		12.1			—
	Change in valuation allowance		2,116.50			—			(29.4	)
	Other		(20.6	)		—			0.6
	Change in tax rate		682.3			—			—
	Credits		228.1			2.1			—
	Effective tax rate		(357.3	)%		54.8	%		0.6	%
	The components of our net deferred tax assets and liabilities at December 31 are as follows:
		2014			2013
		('000s)			('000s)
	Deferred Tax Assets:
	Credits	$	70,219		$	76,023
	Stock options—NQSO		594			1,689
	Fixed assets		831			811
	Accrued Expenses		301			101
	Allowance for doubtful accounts		466			31
	Deferred Rent		97			—
	UNICAP		336			—
	Other		1			—
			72,845			78,655
	Valuation allowance		(72,701	)		(72,601	)
	Net deferred tax assets		144			6,054
	Deferred Tax Liabilities:
			—
	Gain on installment sale		—			(6,054	)
	Other		(144	)		—
			—			—
	We presently have available for federal income tax purposes, approximately $70.5 million of general business credit carry-forwards, which expire beginning in 2025 through 2032. In addition, we have approximately $1.67 million alternative minimum tax credit carry- forwards as of December 31, 2014, which do not expire. In addition, the windfall equity-based compensation deductions are tracked, but will not be recorded to the balance sheet until Management determines that such amounts will be utilized. During 2014, we had $5.4 million, of windfall stock compensation deductions. When realized, the tax benefit associated with these deductions will be credited to additional paid-in capital.
	Our ability to realize its deferred tax assets depends primarily upon the generation of sufficient future taxable income to allow for the utilization of the Company's deductible temporary differences and upon tax planning strategies. Realization of net deferred tax assets is dependent on the Company's ability to generate future taxable income, which is uncertain. We have recorded a valuation allowance of $72.7 million and $72.6 million, against the Company's net deferred tax assets as of December 31, 2014 and December 31 2013, respectively, as Management believes it is more likely than not that the assets will not be realized.
	Utilization of the credit carryforwards may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has not performed a detailed analysis to determine whether an ownership change under Section 382 of the Internal Revenue Code occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of credits attributable to periods before the change and could result in a reduction in the total credits available.
	We are subject to income taxes in the United States and several states. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company had tax net operating losses and credit carryforwards that are subject to examination for a number of years beyond the year in which they are generated for tax purposes. Since a portion of these carryforwards may be utilized in the future, many of these attribute carryforwards remain subject to examination.
	Our policy is to recognize interest and penalties related to income tax matters in income tax expense. As of December 31, 2014 and December 31, 2013, we had no accruals for interest or penalties related to income tax matters.

Defined_Contribution_Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2014
Defined Contribution Plan
Defined Contribution Plan	11. Defined Contribution Plan
	We have a 401(k) plan that is available to all employees. Employee contributions are voluntary and are determined on an individual basis up to the amount allowable under federal regulations. Employer contributions to the plan are at the discretion of the Board of Directors and vest over a seven year period beginning after the third year of eligibility. No employer contributions have been made to date.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies
Commitments and Contingencies	12. Commitments and Contingencies
	Contract Research Organizations.    We utilize independent contract research organizations ("CROs") to perform many of the tasks required under our clinical trials. We rely on CROs for their testing expertise and to ensure the objectivity of our clinical results. Under the terms of these agreements, we design the protocol regarding the testing to be performed, and the CRO assists in the enrollment of the patients and testing sites, administers the trial, performs statistical analysis of the results, and compiles the final report.
	We pay fees directly to the CROs for their professional services, which may be payable upon specified trial milestones or as they provide services, depending on the structure of the contract. We are also responsible for reimbursing the CROs for certain pass thru expenses they incur in administering the trial. The timing of our payments to the CROs is dependent upon the progress of the various trials, which is highly variable dependent upon the speed with which the CROs are able to enroll patients and testing sites. As such, we are unable to specifically predict the timing of future payments to CROs. We may also utilize CROs for future clinical trials.
	The total cost of these future obligations is estimated to be approximately $10.7 million which is expected to be paid through 2017.
	Leases.    During 2006, we entered into a sublease agreement for approximately 61,000 square feet of laboratory, production, warehouse, and office space in Columbia, Maryland. We have also entered into a direct lease with the owner of this facility that was effective as of June 1, 2009 upon the expiration of the sublease and originally expired in July 2016. According to the terms of the lease agreement, we were required to provide a letter of credit which was fully collateralized by restricted cash and as of December 31, 2013, the letter of credit of $243,000 remained outstanding. In September 2014, we entered into an amendment to the operating lease for our Columbia, Maryland facilities, extending the term of the lease through July 2023 and increasing the future minimum lease commitment by $9.0 million. The lease amendment includes an allowance for tenant improvements of approximately $1.5 million that we expect to utilize in 2015 to expand our manufacturing facilities and adjust our office space to accommodate our additional employees. Under the amended lease agreement, we also replaced the $243,000 letter of credit with a $95,000 cash deposit and eliminated all restricted cash.
	The future minimum lease payments due under the operating lease for this facility are as follows:
		Columbia
		Facility
		$0
	2015	$	1,194
	2016		1,091
	2017		1,062
	2018		1,088
	2019		1,218
	Thereafter		4,957
		$	10,610
	Our expenses under this lease were $1.3 million, $1.3 million, and $1.3 million, during 2014, 2013, and 2012, respectively.
	Historically, we also have entered into various financing arrangements to lease laboratory and other equipment. The terms of these facilities and equipment leases are considered capitalized leases.
	As discussed in Note 6 Capital Lease, in July 2012, we leased an additional $228,000 of equipment under a capital lease, which was included in our balance sheets at December 31, 2014 along with $114,100 of accumulated depreciation.
	Legal.    We are subject to certain litigation, claims and assessments which occur in the normal course of business. Based on consultation with our legal counsel, management is of the opinion that there are no matters that are probable or reasonably possible that require accrual or disclosure.

Derivative_and_Securities_Rece

Derivative and Securities Received in Business Disposition	12 Months Ended
	Dec. 31, 2014
Derivative and Securities Received in Business Disposition
Derivative and Securities Received in Business Disposition	13. Derivative and Securities Received in Business Disposition
	The only derivative instrument to which the company was a party was the price protection related to the shares received from Mesoblast as part of the disposition of our Therapeutics business. As discussed in Note 2—Discontinued Operations, the $15 million milestone for completed delivery of the ceMSC assets was payable in either cash or stock, at Mesoblast's election. Because Mesoblast made that payment in stock, the Purchase Agreement provided that these shares were subject to a one year holding period, during which time we were afforded limited protection for any drop in the Mesoblast share price. In the event that the shares decreased in value during the holding period, we would be compensated for 100% of the decrease in value, with 50% of the decrease payable to us in cash, and the remaining 50% again payable in either cash or ordinary shares, at Mesoblast's election. Any additional shares issued would have been subject to an additional one year holding period, but would not be afforded price protection.
	The price protection was recorded as a part of the initial consideration received under the Purchase Agreement at its fair value as of that date of $1.7 million. We evaluated this downside protection, and determined that it met the criteria of a derivative instrument under ASC 815. As such, the price protection derivative was re-measured at its fair value with change in fair value recorded in net income as a component of "Other income".
	In December, the price protection for the Mesoblast ordinary shares expired, but Mesoblast agreed to pay us no less than $15 million in cash for the stock prior to the end of the first half of fiscal 2015. Accordingly, we no longer have a derivative instrument as of December 31, 2014. The fair value of the price protection derivative was $1.7 million as of December 31, 2013, which was included as a component of "Trading Securities." From the closing of the sale of the Therapeutics business through December 31, 2014 and 2013, respectively, we recorded a loss of $1.7 million and $52,000 on the price protection, which was included as a component of "Other income."
	The shares of Mesoblast to which the price protection relates were received by the Company on December 18, 2013 and were required to be held for one year from the date of receipt. The fair value of the shares when they were received was $15 million. The Company elected to remeasure the Mesoblast shares at fair value, with changes in fair value being recorded as a component of "Other income". As such, the statement of comprehensive (loss) income impact of changes in the fair value of the Mesoblast shares and the statement of comprehensive (loss) income impact of changes in the fair value of the price protection derivative largely offset each other during the mandatory holding.
	The fair value of the Mesoblast shares as of December 31, 2014 and 2013, determined by reference to the trading price of identical Mesoblast ordinary shares on the Australian Securities Exchange, was $10.6 million and $15.4 million, respectively. The gain during the period from December 18, 2013 through December 31, 2013 was $401,000. The loss during the year ended December 31, 2014 was $401,000. The difference of $4.4 million between the fair value of the Mesoblast shares, and the guaranteed payment of $15 million is included in "Other Receivables" on our Balance Sheets as of December 31, 2014.

Fair_Value

Fair Value	12 Months Ended
	Dec. 31, 2014
Fair Value
Fair Value
	14. Fair Value
	14. Fair Value
	Fair value is defined as the price at which an asset could be exchanged or a liability transferred (an exit price) in an orderly transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or inputs are not available, valuation models are applied.
	Financial assets recorded at fair value in the accompanying financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, and are as follows:
	Level 1	Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
		The fair valued assets we hold that are generally included in this category are money market securities and the Mesoblast shares received in the disposition of the Therapeutics business, where fair value is based on publicly quoted prices.
	Level 2	Inputs are other than quoted prices included in Level 1, which are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument's anticipated life.
		The fair valued assets we hold that are generally included in this category are investment grade short-term securities and our derivative instrument.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management's best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
		The only asset we hold that is included in this category is the price protection derivative related to the Mesoblast shares received in the disposition of our Therapeutics business.
	When quoted prices in active markets for identical assets are available, we use these quoted market prices to determine the fair value of financial assets and classify these assets as Level 1. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, we obtain the fair value from a third party vendor that uses pricing models, such as matrix pricing, to determine fair value. These financial assets would then be classified as Level 2. In the event quoted market prices were not available, we would determine fair value using broker quotes or an internal analysis of each investment's financial statements and cash flow projections. In these instances, financial assets would be classified based upon the lowest level of input that is significant to the valuation. Thus, financial assets might be classified in Level 3 even though there could be some significant inputs that may be readily available. There have been no transfers between level 1 and 2.
	The price protection derivative related to the Mesoblast shares was classified in Level 3. Its fair value was determined through use of the Black-Scholes valuation method, a standard industry methodology for valuing equity options, because the price protection is economically equivalent to a put option on the Mesoblast shares at a price of $15 million. Significant inputs to the model include the following:
	Fair value of underlying Mesoblast stock: $15,000,000
	Contractual life: 1.0 year
	Volatility: 40%
	Risk-free interest rate: 0.13%
	Expected dividends: $0
	The price protection related to Mesoblast shares ended in December 2014. There were no other transfers in and out of Level 3. The following table represents a rollforward of the fair value of Level 3 instruments, comprised solely of the limited price protection derivative related to the Mesoblast stock issued to us in connection with the sale of our former Therapeutics business:
		December 31,			December 31,
		2014			2013
		(S000s)			(S000s)
	Balance at beginning of period	$	1,685		$	—
	Fair value upon receipt of Mesoblast stock		—			1,737
	Change in fair value		2,252			(52	)
	Expiration of the price protection derivative		(3,937	)		—
	Balance at end of period	$	—		$	1,685
	Assets and liabilities measured at fair value on a recurring basis are summarized below as of December 31, 2014 and 2013:
		December 31, 2014
		($000s)
		Level I			Level II			Level III		Total
	Assets
	Investments: Available for Sale Securities
	Cash & Cash Equivalents	$	1,043			—			—	$	1,043
	US & International government agencies		—			5,679			—		5,679
	Agency Obligations		—			5,385			—		5,385
	Corporate Debt Securities & Commercial Paper		—			12,832			—		12,832
	Municipal Securities		—			12,366			—		12,366
	Total investments available for sale	$	1,043		$	36,262		$	—	$	37,305
	Securities received in business disposition
	Restricted shares of Mesoblast common stock	$	10,591		$	—		$	—	$	10,591
	Total securities		10,591			—			—		10,591
	Total assets	$	11,634		$	36,262		$	—	$	47,896
		December 31, 2013
		($000s)
		Level I			Level II			Level III		Total
	Assets
	Investments: Available for Sale Securities
	Cash & Cash Equivalents	$	655		$	—		$	—	$	655
	US & International government agencies					9,244					9,244
	Certificates of Deposit					4,076					4,076
	Agency Obligations					6,674					6,674
	Corporate Debt Securities & Commercial Paper					6,367					6,367
	Municipal Securities					12,492					12,492
	Total investments available for sale		655			38,853			—		39,508
	Derivative and securities received in business disposition
	Restricted shares of Mesoblast common stock		15,401			—			—		15,401
	Price protection on restricted shares of Mesoblast common stock		—			—			1,685		1,685
	Total derivative instruments and securities		15,401			—			1,685		17,086
	Total assets	$	16,056		$	38,853		$	1,685	$	56,594

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited)	15. Quarterly Financial Data (Unaudited)
	Following is a summary of our unaudited quarterly results for the years ended December 31, 2014 and 2013:
			First Quarter			Second Quarter			Third Quarter			Fourth Quarter
			(000s)			(000s)			(000s)			(000s)
	2014
	Product revenues		$	10,054		$	13,290		$	17,204		$	19,319
	Gross profit			7,842			10,366			13,419			15,069
	Research and development expenses			670			1,055			1,207			3,930
	Selling, general and administrative expenses and fees			7,787			9,377			10,993			9,959
	Loss (income) from continuing operations			(611	)		(1,428	)		710			1,083
	Loss from discontinued operations			(754	)		(457	)		(65	)		(267	)
	Net (loss) income			(1,365	)		(1,885	)		645			816
	**(Loss) income from continuing operations per share, basic and diluted		$	(0.02	)	$	(0.04	)	$	0.02		$	0.03
	**(Loss) income from discontinued operations per share, basic and diluted		$	(0.02	)	$	(0.01	)	$	0		$	(0.01	)
	**Net (loss) income per share, basic and diluted		$	(0.04	)	$	(0.05	)	$	0.02		$	0.02
	2013
	Product revenues		$	4,055		$	5,291		$	6,882		$	8,080
	Gross profit			2,920			3,810			5,024			5,898
	Research and development expenses			957			1,132			913			1,950
	Selling, general and administrative expenses and fees			2,646			4,157			4,602			4,128
	Loss (income) from continuing operations			(654	)		(1,454	)		(466	)		1,481
	Loss from discontinued operations			(2,081	)		(2,302	)		(1,211	)		48,325
	Net (loss) income			(2,735	)		(3,756	)		(1,677	)		49,806
	**(Loss) income from continuing operations per share, basic and diluted		$	(0.02	)	$	(0.04	)	$	(0.01	)	$	0.03
	**(Loss) income from discontinued operations per share, basic		$	(0.06	)	$	(0.07	)	$	(0.04	)	$	1.46
	**(Loss) income from discontinued operations per share, diluted		$	(0.06	)	$	(0.07	)	$	(0.04	)	$	1.43
	**Net loss per share, basic		$	(0.08	)	$	(0.11	)	$	(0.05	)	$	1.49
	**Net loss per share, diluted		$	(0.08	)	$	(0.11	)	$	(0.05	)	$	1.46
	**	(Loss) income per share is calculated on a quarterly basis and may not be additive to year-to-date amounts.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events
Subsequent Events	16. Subsequent Events
	We evaluated our December 31, 2014 financial statements for subsequent events through the date the financial statements were issued. Pursuant to the exclusive distribution agreement we entered into with a subsidiary of Stryker Corporation in December 2014, we received the initial exclusivity fee of $5 million from Stryker in February 2015. This fee was required to be paid by Stryker within five business days of receipt of documents outlined in the December 2014 agreement. We are not aware of any other subsequent events which would require recognition or disclosure in the financial statements.

SCHEDULE_IIVALUATION_AND_QUALI

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2014
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS	OSIRIS THERAPEUTICS, INC.
	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
	FOR THE YEARS ENDED DECEMBER 31, 2014, 2013 AND 2012
	(in thousands)
		Balance at		Additions		Deductions			Balance at
		Beginning of							End of Year
		Year
	Accounts Receivable Reserve:
	2014	$	78	$	1,178	$	—		$	1,256
	2013		25		80		(27	)		78
	2012		3		22		—			25
	Inventory Reserve:
	2014	$	—	$	—	$	—		$	—
	2013		112		—		(112	)		—
	2012		274		—		(162	)		112
	Net Deferred Tax Asset Valuation Allowance:
	2014	$	72,601	$	100	$	—		$	72,701
	2013		88,243		—		(15,642	)		72,601
	2012		84,134		4,109		—			88,243

Description_of_Business_and_Si1

Description of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Description of Business and Significant Accounting Policies
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Due to the inherent uncertainty involved in making those assumptions, actual results could differ from those estimates. We believe that the most significant estimates that affect our financial statements are those that relate to deferred tax assets, inventory valuation, share-based compensation and the value of the derivative obtained in connection with the sale of our former Therapeutics business.
Cash and Cash Equivalents	Cash and Cash Equivalents
	Amounts listed as cash on our balance sheets are maintained in depository accounts at a commercial bank. Cash and cash equivalents, which include highly liquid investments with maturities of three months or less when purchased, held in our brokerage investment accounts are classified as investments available for sale, as the amounts represent investments that have matured and are anticipated to be reinvested in debt securities in the near future, and are disclosed at fair value, which approximates cost.
Reclassifications	Reclassifications
	We have reclassified certain prior-year amounts for comparative purposes. These reclassifications did not affect our results of operations or financial positions for the years presented.
Investments Available for Sale	Investments Available for Sale
	Investments available for sale consist primarily of marketable securities with maturities less than one year. Investments available for sale are valued at their fair value, with unrealized gains and losses reported as a separate component of stockholders' equity in accumulated other comprehensive income. All realized gains and losses on our investments available for sale are recognized in results of operations as other income.
	Investments available for sale are evaluated periodically to determine whether a decline in their value is "other than temporary." The term "other than temporary" is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. We review criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. If a decline in value is determined to be other than temporary, the carrying value of the security is reduced and a corresponding charge to earnings is recognized.
Restricted Cash	Restricted Cash
	We periodically are required under the terms of various agreements to provide letters of credit which are collateralized by cash deposits. The majority of the restricted cash balance relates to a letter of credit that we caused to be issued in lieu of a security deposit under the operating lease for our Columbia, Maryland facility.
Trade Accounts Receivable	Trade Accounts Receivable
	Trade accounts receivable are reported at their net realizable value. We charge off uncollectible receivables when the likelihood of collection is remote. We set credit terms with individual customers, and consider receivables outstanding longer than the time specified in the respective customer's contract, typically 45-days, to be past due. As of December 31, 2014 and 2013, accounts receivable in the accompanying balance sheets are reported net of a $1,256,000 and a $78,000 allowance for doubtful accounts, respectively. We believe the reported amounts are fully collectible. Trade accounts receivable balances are not collateralized. We have incurred bad debt expense of $1,178,000, $80,000 and $22,000 related to our Biosurgery operations during fiscal 2014, 2013 and 2012, respectively.
Inventory	Inventory
	We began carrying inventory of our Biosurgery products on our balance sheet following commercial launch of such products. Inventory consists of raw materials, biologic products in process, and products available for distribution. We determine our inventory values using the first-in, first-out method. Inventory is valued at the lower of cost or market, and excludes units that we anticipate distributing for clinical evaluation.
Property and Equipment	Property and Equipment
	Property and equipment, including improvements that extend useful lives, are valued at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the
	straight-line method based on estimated useful lives ranging from three to seven years for furniture, equipment and internal use software. Leasehold improvements and assets under capital leases are amortized over the shorter of the estimated useful life of the asset or the original term of the lease.
Valuation of Long-lived Assets	Valuation of Long-lived Assets
	We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, we evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. There were no impairment losses recognized during fiscal years 2014, 2013 or 2012.
Derivative and Securities Received in Business Disposition	Derivative and Securities Received in Business Disposition
	As discussed in Note 2—Discontinued Operations, we disposed of our Therapeutics segment in October 2013. A portion of the consideration for the sale of that business was stock of Mesoblast Limited ("Mesoblast"), the parent of the purchaser. We were required to hold that stock for one year from the date of receipt. We intended to dispose of the Mesoblast stock as soon as we were able to do so. Mesoblast is a public company and its stock is traded on the Australian stock exchange. As of December 31, 2014 and 2013, we reflect the investment as a current asset in Trading Securities. In December 2014, the price protection on these shares expired, but Mesoblast agreed to pay us $15 million in cash for the stock in the first half of fiscal 2015. Accordingly, as of December 31, 2014, this $15 million is shown as $10.6 million in Trading Securities and $4.4 million in Other Receivables on our Balance Sheets.
	The Mesoblast stock was previously subject to limited price protection for the one year required holding period. To the extent the value of those shares decreased during the holding period, Mesoblast was required to pay us for the decrease in value. This payment was to be made at least one half in cash and at the option of Mesoblast, up to one half in additional shares of Mesoblast stock. Any additional Mesoblast stock would also have to be held for one year during which period there was no further price protection. In fiscal 2013, the price protection was accounted for as a derivative under ASC 815, Derivatives and Hedging, and, as such was recorded on the balance sheets at fair value, with changes recognized in net income. We elected to measure the Mesoblast stock at fair value with changes in fair value reflected in net income, as permitted under ASC 825-10, Financial Instruments—Fair Value Option. The price protection ended in December 2014 and we no longer have a derivative instrument.
	All derivative instruments within the scope of ASC 815, Derivatives and Hedging, are recorded on the balance sheet at fair value. As of December 31, 2013 our only derivative instrument was the price guarantee regarding the payment received in restricted Mesoblast shares described in Note 13—Derivative and Securities Received in Business Disposition below. We do not hold derivative financial instruments for trading purposes.
Biosurgery Revenue Recognition	Biosurgery Revenue Recognition
	We recognize revenue from product distribution when title passes to the customer. Title usually passes when the product is shipped to the customer and leaves our loading dock. In some situations, we store consigned inventory on site in freezers at hospital or clinic facilities. No revenue is recognized upon the placement of inventory into consignment as we retain title and maintain the inventory on our balance sheet. For these products, revenue is recognized when we receive appropriate notification that the product has been used in a surgical procedure. We verify the condition and status of all consigned inventory on at least a quarterly basis. Due to the nature of our products and the need to ensure they are maintained at the proper frozen temperature, we generally do not allow product returns.
	In December 2014, we entered into exclusive distribution agreements with a subsidiary of Stryker Corporation for the marketing and distribution of BIO4, our viable bone matrix allograft. Pursuant to the agreement, Stryker has been granted worldwide distribution rights to the product and any improvements, for all surgical applications. We will be responsible for supply, manufacturing, inventory management, shipments to customers, continued research and product improvement activities. We will recognize as revenue the amounts charged to customers for the allografts and related services. Commissions and administrative fees paid to Stryker will be accounted for as selling expenses, as Stryker is acting as outside sales and marketing agent for Osiris. We are entitled to receive an initial exclusivity fee of $5.0 million and additional fees upon any exercise by Stryker of its right to extend the initial term, whether on an exclusive or non-exclusive basis. The exclusivity fee and any extension fees subsequently received are considered to be adjustments of the selling expenses. As such, we recognize the exclusively fee as a liability and will be amortized over the related exclusivity period in proportion to the expected fees to be paid to Stryker, as an offset to selling expenses. At December 31, 2014, Osiris recorded a $5.0 million receivable included in other receivables with the offset to short-term deferred commissions of $1.67 million and long-term deferred commissions $3.33 million included in other long term liabilities.
	In October 2014, we entered into an exclusive commercial and development partnership for our cartilage product, Cartiform, with Arthrex, Inc. The agreement provides Arthrex with exclusive commercial distribution rights to Cartiform beginning in 2015. We will be responsible for manufacturing, continued research and product improvement activities. The responsibilities related to the design and conduct of future clinical development programs will be shared between both organizations. Pursuant to the agreement, Arthrex is entitled to a certain commission on Cartiform sales. We will recognize the full sales price as revenue and account for the payment to Arthrex as commission expense.
Therapeutics Revenue Recognition	Therapeutics Revenue Recognition
	In our former Therapeutics business, we evaluated revenues from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting. To recognize a delivered item in a multiple element arrangement, the delivered items must have value on a standalone basis and the delivery or performance must be probable and within our control for any delivered items that have a right of return. The determination of whether multiple elements of a collaboration agreement meet the criteria for separate units of accounting requires us to exercise judgment. We account for the activities of our former Therapeutics business as discontinued operations.
	Revenues from research licenses associated with our former Therapeutics business were recognized as earned upon either the incurring of reimbursable expenses directly related to the particular research plan or the completion of certain development milestones as defined within the terms of the agreement. Payments received in advance of research performance were designated as deferred revenue. Non-refundable upfront license fees and certain other related fees associated with our former Therapeutics business were recognized on a straight-line basis over the development periods of the contract deliverables. Fees associated with substantive at risk performance based milestones are recognized as revenue upon their completion, as defined in the respective agreements. Incidental assignment of technology rights were recognized as revenue when and if it was earned and received.
	In October 2008, we entered into a Collaboration Agreement with Genzyme Corporation, then an independent and now a Sanofi company ("Genzyme"), for the development and commercialization of our biologic drug candidates, Prochymal and Chondrogen™. Under this agreement, Genzyme made non-contingent, non-refundable cash payments to us, totaling $130 million. The agreement provided Genzyme with certain rights to intellectual property developed by us, and required that we continue to perform certain development work related to the subject biologic drug candidates. In February 2012, Sanofi issued a press release which included an update on their R&D pipeline, stating that it had discontinued its project with Prochymal for GvHD. In September 2012, we reached agreement with Sanofi to conclude the Collaboration Agreement without either party having any continuing obligation to the other.
	We evaluated the deliverables related to the upfront payments made to us under the Genzyme collaboration agreement, and concluded that the various deliverables represent a single unit of accounting. For this reason, we deferred the recognition of revenue related to the upfront payments, and amortized these amounts to revenue on a straight-line basis over the estimated delivery period of the required development services, which extended through January 2012.
Research and Development Costs	Research and Development Costs
	We expense internal and external research and development ("R&D") costs, including costs of funded R&D arrangements and the manufacture of clinical batches of Biosurgery products used in clinical trials, in the period incurred.
	Internal resources are applied interchangeably across several product candidates due to the potential applicability of our biologic drug candidates for multiple indications.
Income Taxes	Income Taxes
	Deferred tax liabilities and assets are recognized for the estimated future tax consequences of temporary differences, income tax credits and net operating loss carry-forwards. Temporary differences are primarily the result of the differences between the tax bases of assets and liabilities and their financial reporting values. Deferred tax liabilities and assets are measured by applying the enacted statutory tax rates applicable to the future years in which deferred tax liabilities or assets are expected to be settled or realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense, if any, consists of the taxes payable for the current period and the change during the period in deferred tax assets and liabilities.
	We recognize in our financial statements the impact of a tax position, if that position is more likely than not to be sustained upon an examination, based on the technical merits of the position. Interest and penalties related to income tax matters are recorded as income tax expense. At December 31, 2014 and 2013, we had no accruals for interest or penalties related to income tax matters.
Income per Common Share	Income per Common Share
	Basic income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted income per common share adjusts basic income per share for the potentially dilutive effects of common share equivalents, using the treasury stock method, and includes the incremental effect of shares that would be issued upon the assumed exercise of stock options and warrants.
	Diluted loss from continuing operations for the year ended December 31, 2014 excluded all 1,608,557 shares issuable upon the exercise of options, as their impact on our loss from continuing operations is anti-dilutive. As a result, basic and diluted weighted average common shares outstanding are identical.
	Diluted loss from continuing operations for the year ended December 31, 2013 excluded all 1,233,767 shares issuable upon the exercise of options, as their impact on our loss from continuing operations is anti-dilutive. As a result, basic and diluted weighted average common shares outstanding are identical.
	Diluted loss per common share for the year ended December 31, 2012 excludes the 1,000,000 shares issuable upon the exercise of an outstanding "out-of the money" warrant, and all 1,826,114 of our outstanding options as of December 31, 2012, as their impact on our net loss is anti-dilutive. As a result, basic and diluted weighted average common shares outstanding are identical.
Share-Based Compensation	Share-Based Compensation
	We account for share-based payments using the fair value method.
	We recognize all share-based payments to employees and non-employee directors in our financial statements based on their grant date fair values, calculated using the Black-Scholes option pricing model. Compensation expense related to share-based awards is recognized on a straight-line basis for each vesting tranche based on the value of share awards that are expected to vest on the grant date, which is revised if actual forfeitures differ materially from original expectations.
Comprehensive Income (Loss)	Comprehensive Income
	Comprehensive income consists of net income and all changes in equity from non-stockholder sources, which consist of changes in unrealized gains and losses on investments.
Concentration of Risk	Concentration of Risk
	We maintain cash and short-term investment balances in accounts that exceed federally insured limits, although we have not experienced any losses on such accounts. We also invest excess cash in investment grade securities, generally with maturities of one year or less.
	We have historically provided credit in the normal course of business to contract counterparties and to the distributors of our product. Trade accounts receivable in the accompanying balance sheets consist primarily of amounts due from distributors of our Biosurgery products within the United States. During fiscal 2014 and 2013 respectively, revenues from one of the distributors of our Biosurgery products, Stability Biologics, comprised approximately 10% and 50% of our total Biosurgery revenues. As of December 31, 2014 and 2013 respectively, receivables from this distributor comprised 13% and 6% of our total receivables. As discussed under "Trade Accounts Receivable" above, we have incurred bad debt expense of $1,178,000, $80,000 and $22,000 for the three years ended December 31, 2014, 2013 and 2012, respectively.
Recently Adopted Accounting Guidance at June 30, 2014	Recent Accounting Guidance Not Yet Adopted at December 31, 2014
	In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers," which requires an entity to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application. We are currently assessing the impact the adoption of ASU 2014-09 will have on our financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements—Going Concern," which require management to evaluate, at each reporting period, whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently assessing the impact the adoption of ASU 2014-15 will have on our financial statements.

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Discontinued Operations
Schedule of initial consideration and contingent additional payments upon achievement of milestone events provided under Purchase Agreement
	Milestone	Amount
		$0
	Initial consideration
	Letter of intent payments	$	3,500
	Initial closing payment		16,500
	Additional closing payment, 6 months after closing date		15,000
	Delivery of all scheduled assets under the Transfer Agreement		15,000
	Total initial consideration		50,000
	Contingent onsideration
	First marketing authorization received in the U.S.		20,000
	First marketing authorization received from France, Germany, or European Union		10,000
	Completion of the enrollment of the Phase 3 Crohn's Trial or Mesoblast's election to discontinue the trial		10,000
	Receipt of final data for the Crohn's trial or first marketing approval for Crohn's		10,000
	Total conditional consideration		50,000
	Total possible purchase price	$	100,000
Schedule of net assets allocable to the Therapeutics business	The net assets allocable to the Therapeutics business at December 31, 2014 and 2013 were as follows:
		2014			2013
		($000s)			($000s)
	Current assets:
	Accounts receivable	$	—		$	91
	Current liabilities:
	Accounts payable and accrued expenses	$	—		$	57
Summary of operating results of discontinued operations
		Year ended
		December 31, ($000s)
		2014			2013			2012
	Revenue from collaborative research agreements and royalties	$	288		$	639		$	3,955
	Operating expenses:
	Research and development	$	299			6,426			8,607
	Selling, general and administrative		591			881			666
			890			7,307			9,273
	Loss from discontinued operations before income tax expense		(602	)		(6,668	)		(5,318	)
	Income tax expense		(941	)		—			—
	Loss from discontinued operations	$	(1,543	)	$	(6,668	)	$	(5,318	)

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property and Equipment
Schedule of property and equipment	Property and equipment at December 31, 2014 and 2013 are as follows:
		2014			2013
		($000s)			($000s)
	Laboratory and manufacturing equipment	$	1,211		$	663
	Computer hardware, furniture and fixtures		1,377			899
	Leased assets		228			228
	Leasehold improvements		4,365			4,260
			7,181			6,050
	Accumulated depreciation and amortization		(5,094	)		(4,154	)
	Property and equipment, net	$	2,087		$	1,896

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory
Schedule of inventory for Biosurgery business	As of December 31, 2014 and 2013, inventory for our Biosurgery business consists of the following:
		2014		2013
		($000s)		($000s)
	Inventory
	Raw materials and supplies	$	1,025	$	387
	Work-in-process		465		22
	Finished goods		9,434		1,520
	Total Biosurgery inventory, net		10,924		1,929

Capital_Lease_Tables

Capital Lease (Tables)	12 Months Ended
	Dec. 31, 2014
Capital Lease
Schedule of future minimum lease payments under the capital lease agreement	Future minimum lease payments under the capital lease agreement at December 31, 2014 are as follows:
	December 31,	Amount
		(000s)
	2015	$	48
	2016		48
	2017		24
			120
	Less: Amount representing interest		(3	)
	Present value of minimum lease payments		117
	Less: Current portion of capital lease obligations		(45	)
	Long-term portion of capital lease obligations		72

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Share-Based Compensation
Schedule of assumptions used to estimate fair value of stock options granted
		Years ended December 31,
		2014			2013			2012
	Assumptions:
	Weighted average risk-free interest rate		1.50	%		1.00-1.50	%		2.00	%
	Dividend yield		0.00	%		0.00	%		0.00	%
	Expected life of option grants		5.0 yrs			5.0-6.5 yrs			6.0-6.3 yrs
	Weighted average expected stock price volatility		60	%		52-61	%		52-54	%
Summary of stock option activity
		Number of			Weighted			Weighted		Aggregate
		Shares			Average			Average		Intrinsic Value
					Exercise			Remaining		(in thousands)
					Price			Contractual Life
	Balance, December 31, 2011		1,702,072		$	9.06		6.8 years
	Granted		302,000		$	5.5
	Exercised		(28,708	)	$	(3.05	)			$	114
	Forfeited or canceled		(149,250	)	$	(7.20	)
	Balance, December 31, 2012		1,826,114		$	8.72		6.1 years		$	4,754
	Granted		452,000		$	9.03
	Exercised		(642,514	)	$	(6.50	)			$	6,983
	Forfeited or canceled		(401,833	)	$	(6.79	)
	Balance, December 31, 2013		1,233,767		$	10.61		6.3 years		$	7,992
	Granted		988,500		$	14.59
	Exercised		(204,085	)	$	8.25				$	1,341
	Forfeited or canceled		(409,625	)	$	15.92
	Balance, December 31, 2014		1,608,557		$	12.01		7.92 years		$	6,774
	Exercisable at December 31, 2014		400,432		$	9.79		5.04 years		$	2,759
Summary of stock options outstanding by price range	A summary of stock options outstanding at December 31, 2014, by price range is as follows:
		Options Outstanding									Options Exercisable
	Range of	Number			Weighted-Average			Weighted-Average			Number		Weighted-Average
	Exercise Prices	Outstanding			Remaining			Exercise			Outstanding		Exercise Price
					Contractual Life			Price
					(in years)
	$0.40-$4.00		8,813			0.9		$	0.40			8,813	$	0.40
	$4.01-$5.25		133,790			7.1			5.31			51,790		5.08
	$5.26-$7.25		171,815			5.4			6.89			121,065		6.85
	$7.01-$7.75		210,139			7.3			7.73			86,764		7.74
	$7.76-$8.50		6,625			7.9			8.22			750		7.80
	$8.51-$12.75		151,375			7.9			11.42			42,750		11.23
	$12.76-$14.00		342,000			9.4			13.51			8,250		13.00
	$14.01-$16.00		290,000			9.3			15.01			—		—
	$16.01-$17.50		230,500			8.7			16.48			16,750		17.08
	$17.51-$24.00		63,500			3.6			20.03			63,500		20.03
			1,608,557			8.0		$	12.01			400,432	$	9.79
Schedule of share-based compensation expense
		Year Ended December 31,
		2014			2013			2012
		(000s)			(000s)			(000s)
	Research and development		1,802			335			238
	Selling, general and administrative		1,330			248			254
	Discontinued operations		—			658			598
	Total		3,132			1,241			1,090

Investments_Available_for_Sale1

Investments Available for Sale (Tables)	12 Months Ended
	Dec. 31, 2014
Investments Available for Sale
Schedule of investments available for sale
		December 31, 2014											December 31, 2013
		($000s)											($000s)
				Unrealized											Unrealized
		Cost		Gain			Loss			Fair Value			Cost		Gain			Loss			Fair Value
	Cash equivalents:
	Money market funds & certificates of deposit	$	1,043	$	—		$	—		$	1,043		$	655	$	—		$	—		$	655
	Corporate debt securities & commercial paper		12,835		21			(24	)		12,832			6,355		22			(10	)		6,367
			13,878		21			(24	)		13,875			7,010		22			(10	)		7,022
	Investments:
	Municipal securities		12,400		13			(47	)		12,366			12,507		9			(24	)		12,492
	Agency obligations		5,401		12			(28	)		5,385			6,704		5			(35	)		6,674
	Mutual Funds		—		—			—			—			4,076		—			—			4,076
	US & International government agencies		5,680		1			(2	)		5,679			9,244		—			—			9,244
			23,481		26			(77	)		23,430			32,531		14			(59	)		32,486
	Investments available for sale	$	37,359	$	47		$	(101	)	$	37,305		$	39,541	$	36		$	(69	)	$	39,508
Summary of securities with unrealized losses
		Less than 12 Months					12 Months or More						Total
		Fair		Unrealized			Fair			Unrealized			Fair		Unrealized
		Value		Loss			Value			Loss			Value		Loss
	12/31/2014 ($000s)
	Municipal securities	$	1,000	$	(1	)	$	1,032		$	(46	)	$	2,032	$	(47	)
	Agency obligations		3,939		(28	)		—			—			3,939		(28	)
	Corporate debt securities & commercial paper		7,073		(24	)		—			—			7,073		(24	)
	US & International government agencies		2,873		(2	)		—			—			2,873		(2	)
	Total temporarily impaired	$	14,885	$	(55	)	$	1,032		$	(46	)	$	15,917	$	(101	)
		Less than 12 months					More than 12 months						Total
		Fair		Unrealized			Fair			Unrealized			Fair		Unrealized
		Value		Loss			Value			Loss			Value		Loss
	12/13/2013 ($000s)
	Corporate debt securities & commercial paper	$	3,341	$	(10	)	$	—		$	—		$	3,341	$	(10	)
	Municipal securities		4,530		(24	)		—			—			4,530		(24	)
	Agency obligations		3,804		(35	)		—			—			3,804		(35	)
	Total temporarily impaired	$	11,675	$	(69	)	$	—		$	—		$	11,675	$	(69	)
Schedule of maturities of investments available for sale
		December 31, 2014					December 31, 2013
		($000s)					($000s)
		Cost		Fair Value			Cost			Fair Value
	Maturities:
	Within 3 months	$	3,056	$	3,056		$	12,663		$	12,664
	Between 3-12 months		12,658		12,660			1,624			1,610
	More than 1 year		21,645		21,589			25,254			25,234
	Investments available for sale	$	37,359	$	37,305		$	39,541		$	39,508

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes
Schedule of effective tax rate benefit (expense) that varies from the U.S. Federal Statutory tax rate
		2014			2013			2012
	U.S. Federal Statutory tax rate		35	%		35	%		35	%
	State taxes, net of federal benefits		(306.6	)		7			—
	Nondeductible expenses		(329.2	)		(1.4	)		(5.6	)
	Stock compensation		(2,762.8	)		12.1			—
	Change in valuation allowance		2,116.50			—			(29.4	)
	Other		(20.6	)		—			0.6
	Change in tax rate		682.3			—			—
	Credits		228.1			2.1			—
	Effective tax rate		(357.3	)%		54.8	%		0.6	%
Schedule of components of net deferred tax assets and liabilities	The components of our net deferred tax assets and liabilities at December 31 are as follows:
		2014			2013
		('000s)			('000s)
	Deferred Tax Assets:
	Credits	$	70,219		$	76,023
	Stock options—NQSO		594			1,689
	Fixed assets		831			811
	Accrued Expenses		301			101
	Allowance for doubtful accounts		466			31
	Deferred Rent		97			—
	UNICAP		336			—
	Other		1			—
			72,845			78,655
	Valuation allowance		(72,701	)		(72,601	)
	Net deferred tax assets		144			6,054
	Deferred Tax Liabilities:
			—
	Gain on installment sale		—			(6,054	)
	Other		(144	)		—
			—			—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies
Schedule of future minimum lease payments due under the operating lease
		Columbia
		Facility
		$0
	2015	$	1,194
	2016		1,091
	2017		1,062
	2018		1,088
	2019		1,218
	Thereafter		4,957
		$	10,610

Fair_Value_Tables

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value
Schedule of significant inputs used to measure fair value using Black-Scholes valuation method
	Fair value of underlying Mesoblast stock: $15,000,000
	Contractual life: 1.0 year
	Volatility: 40%
	Risk-free interest rate: 0.13%
	Expected dividends: $0
Schedule of rollforward of the fair value of Level 3 instruments, comprised solely of the limited price protection derivative related to the Mesoblast stock issued to entity in connection with the sale of entity's former Therapeutics business
		December 31,			December 31,
		2014			2013
		(S000s)			(S000s)
	Balance at beginning of period	$	1,685		$	—
	Fair value upon receipt of Mesoblast stock		—			1,737
	Change in fair value		2,252			(52	)
	Expiration of the price protection derivative		(3,937	)		—
	Balance at end of period	$	—		$	1,685
Schedule of assets and liabilities measured at fair value on a recurring basis
		December 31, 2014
		($000s)
		Level I			Level II			Level III		Total
	Assets
	Investments: Available for Sale Securities
	Cash & Cash Equivalents	$	1,043			—			—	$	1,043
	US & International government agencies		—			5,679			—		5,679
	Agency Obligations		—			5,385			—		5,385
	Corporate Debt Securities & Commercial Paper		—			12,832			—		12,832
	Municipal Securities		—			12,366			—		12,366
	Total investments available for sale	$	1,043		$	36,262		$	—	$	37,305
	Securities received in business disposition
	Restricted shares of Mesoblast common stock	$	10,591		$	—		$	—	$	10,591
	Total securities		10,591			—			—		10,591
	Total assets	$	11,634		$	36,262		$	—	$	47,896
		December 31, 2013
		($000s)
		Level I			Level II			Level III		Total
	Assets
	Investments: Available for Sale Securities
	Cash & Cash Equivalents	$	655		$	—		$	—	$	655
	US & International government agencies					9,244					9,244
	Certificates of Deposit					4,076					4,076
	Agency Obligations					6,674					6,674
	Corporate Debt Securities & Commercial Paper					6,367					6,367
	Municipal Securities					12,492					12,492
	Total investments available for sale		655			38,853			—		39,508
	Derivative and securities received in business disposition
	Restricted shares of Mesoblast common stock		15,401			—			—		15,401
	Price protection on restricted shares of Mesoblast common stock		—			—			1,685		1,685
	Total derivative instruments and securities		15,401			—			1,685		17,086
	Total assets	$	16,056		$	38,853		$	1,685	$	56,594

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data (Unaudited)
Schedule of unaudited quarterly results	Following is a summary of our unaudited quarterly results for the years ended December 31, 2014 and 2013:
			First Quarter			Second Quarter			Third Quarter			Fourth Quarter
			(000s)			(000s)			(000s)			(000s)
	2014
	Product revenues		$	10,054		$	13,290		$	17,204		$	19,319
	Gross profit			7,842			10,366			13,419			15,069
	Research and development expenses			670			1,055			1,207			3,930
	Selling, general and administrative expenses and fees			7,787			9,377			10,993			9,959
	Loss (income) from continuing operations			(611	)		(1,428	)		710			1,083
	Loss from discontinued operations			(754	)		(457	)		(65	)		(267	)
	Net (loss) income			(1,365	)		(1,885	)		645			816
	**(Loss) income from continuing operations per share, basic and diluted		$	(0.02	)	$	(0.04	)	$	0.02		$	0.03
	**(Loss) income from discontinued operations per share, basic and diluted		$	(0.02	)	$	(0.01	)	$	0		$	(0.01	)
	**Net (loss) income per share, basic and diluted		$	(0.04	)	$	(0.05	)	$	0.02		$	0.02
	2013
	Product revenues		$	4,055		$	5,291		$	6,882		$	8,080
	Gross profit			2,920			3,810			5,024			5,898
	Research and development expenses			957			1,132			913			1,950
	Selling, general and administrative expenses and fees			2,646			4,157			4,602			4,128
	Loss (income) from continuing operations			(654	)		(1,454	)		(466	)		1,481
	Loss from discontinued operations			(2,081	)		(2,302	)		(1,211	)		48,325
	Net (loss) income			(2,735	)		(3,756	)		(1,677	)		49,806
	**(Loss) income from continuing operations per share, basic and diluted		$	(0.02	)	$	(0.04	)	$	(0.01	)	$	0.03
	**(Loss) income from discontinued operations per share, basic		$	(0.06	)	$	(0.07	)	$	(0.04	)	$	1.46
	**(Loss) income from discontinued operations per share, diluted		$	(0.06	)	$	(0.07	)	$	(0.04	)	$	1.43
	**Net loss per share, basic		$	(0.08	)	$	(0.11	)	$	(0.05	)	$	1.49
	**Net loss per share, diluted		$	(0.08	)	$	(0.11	)	$	(0.05	)	$	1.46
	**	(Loss) income per share is calculated on a quarterly basis and may not be additive to year-to-date amounts.

Description_of_Business_and_Si2

Description of Business and Significant Accounting Policies (Details) (USD $)	12 Months Ended			48 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
				item
Trade Accounts Receivable
Number of business segments				2
Trade Accounts Receivable
Typical trade accounts receivable due period	45 days
Allowance for doubtful accounts related to accounts receivable	$1,256,000	$78,000		$78,000
Provision for bad debts	1,178,000	80,000	22,000
Other receivables	9,951,000	15,265,000		15,265,000
Deferred commissions payable, current portion	1,667,000
Biosurgery segment
Trade Accounts Receivable
Provision for bad debts	1,178,000	80,000	22,000
Other receivables	5,000,000
Deferred commissions payable, current portion	1,670,000
Deferred commissions payable, non-current portion	$3,330,000

Description_of_Business_and_Si3

Description of Business and Significant Accounting Policies (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Valuation of Long-lived Assets
Impairment losses	$0	$0	$0
Income Taxes
Accruals for interest or penalties related to income tax matters	$0
Minimum
Property and Equipment
Estimated useful lives	3 years
Maximum
Property and Equipment
Estimated useful lives	7 years

Description_of_Business_and_Si4

Description of Business and Significant Accounting Policies (Details 3) (USD $)	0 Months Ended		12 Months Ended
	Dec. 31, 2013	Oct. 10, 2013	Dec. 31, 2014
Derivative and Securities Received in Business Disposition
Trading securities	17,086,000		$10,591,000
Other receivables	15,265,000		9,951,000
Purchase Agreement with Mesoblast
Derivative and Securities Received in Business Disposition
Holding period for any payments made in ordinary shares		1 year
Other receivables			4,400,000
Holding period of stock subject to limited price protection	1 year
Aggregate compensation to be received for decrease in value of shares payable in cash (as a percent)			50.00%
Aggregate compensation to be received for decrease in value of shares (as a percent)			50.00%
Therapeutics segment | Purchase Agreement with Mesoblast
Derivative and Securities Received in Business Disposition
Holding period for any payments made in ordinary shares		1 year
Consideration in restricted stock			15,000,000
Trading securities			10,600,000
Other receivables			$4,400,000

Description_of_Business_and_Si5

Description of Business and Significant Accounting Policies (Details 4) (Genzyme Corporation, USD $)	1 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2008
Genzyme Corporation
Revenue Recognition
Non-contingent, non-refundable cash payments	$130

Description_of_Business_and_Si6

Description of Business and Significant Accounting Policies (Details 5)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrant
Income per Common Share
Anti-dilutive securities not included in diluted income (loss) per common share			1,000,000
Stock options
Income per Common Share
Anti-dilutive securities not included in diluted income (loss) per common share	1,608,557	1,233,767	1,826,114

Description_of_Business_and_Si7

Description of Business and Significant Accounting Policies (Details 6) (Distributors, Biosurgery segment)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
	item
Concentration of Risk
Concentration of risk (as a percent)	0.00%
Receivables
Concentration of Risk
Concentration of risk (as a percent)		6.00%
Revenue
Concentration of Risk
Number of significant distributors	1
Concentration of risk (as a percent)	10.00%	50.00%

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	12 Months Ended				0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 10, 2013
Initial consideration and contingent additional payments provided under Purchase Agreement
Consideration in cash		$19,419,000
Gain on sale of discontinued operations		49,399,000
Income tax expense related to gain from sale of discontinued operation		1,705,000
Current liabilities:
Royalty revenue	0
Operating expenses:
Income tax expense	-941,000	0	0
Loss from discontinued operations	1,543,000	6,668,000	5,318,000
Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Gain on sale of discontinued operations	49,400,000
Current assets:
Accounts Receivable		91,000
Current liabilities:
Accounts payable and accrued expenses		57,000
Contingent milestone payments received	0
Royalty revenue	288,000	215,000	305,000
Summarized operating results
Revenue from collaborative research agreements and royalties	288,000	639,000	3,955,000
Operating expenses:
Research and development	299,000	6,426,000	8,607,000
Selling, general and administrative	591,000	881,000	666,000
Total operating expenses	890,000	7,307,000	9,273,000
Loss from discontinued operations before income tax expense	-602,000	-6,668,000	-5,318,000
Income tax expense	-941,000
Loss from discontinued operations	1,543,000	6,668,000	5,318,000
Cost of reimbursement		0		296,000
Purchase Agreement with Mesoblast
Initial consideration and contingent additional payments provided under Purchase Agreement
Holding period for any payments made in ordinary shares					1 year
Purchase Agreement with Mesoblast | Hedging instrument
Initial consideration and contingent additional payments provided under Purchase Agreement
Fair value of derivative instruments	1,700,000
Purchase Agreement with Mesoblast | Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Initial consideration					50,000,000
Contingent Consideration					50,000,000
Total possible purchase price					100,000,000
Total initial consideration paid in cash					20,000,000
Initial consideration paid in ordinary shares					-15,000,000
Holding period for any payments made in ordinary shares					1 year
Consideration in restricted stock	15,000,000
Initial consideration payable in cash	15,000,000
Transaction costs	600,000
Income tax expense related to gain from sale of discontinued operation	1,700,000
Purchase Agreement with Mesoblast | Letter of intent payments | Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Initial consideration					3,500,000
Purchase Agreement with Mesoblast | Initial closing payment | Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Initial consideration					16,500,000
Purchase Agreement with Mesoblast | Additional closing payment, received in April 2014 | Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Initial consideration					15,000,000
Purchase Agreement with Mesoblast | Delivery of all scheduled assets under the Transfer Agreement | Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Initial consideration					15,000,000
Purchase Agreement with Mesoblast | First marketing authorization received in the U.S. | Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Contingent Consideration					20,000,000
Purchase Agreement with Mesoblast | First marketing authorization received from France, Germany, or European Union | Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Contingent Consideration					10,000,000
Purchase Agreement with Mesoblast | Completion of the enrollment of the Phase 3 Crohn's Trial or Mesoblast's election to discontinue the trial | Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Contingent Consideration					10,000,000
Purchase Agreement with Mesoblast | Receipt of final data for the Crohn's trial or first marketing approval for Crohn's | Therapeutics segment
Initial consideration and contingent additional payments provided under Purchase Agreement
Contingent Consideration					10,000,000

Segment_Reporting_Details

Segment Reporting (Details)	12 Months Ended
	Dec. 31, 2014
	item
Segment Reporting
Number of operating segments historically managed by the entity	2
Number of operating segments	1

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property and Equipment
Property and equipment, gross	$7,181,000	$6,050,000
Accumulated depreciation and amortization	-5,094,000	-4,154,000
Property and equipment, net	2,087,000	1,896,000
Depreciation	940,000	587,000	552,000
Laboratory and manufacturing equipment
Property and Equipment
Property and equipment, gross	1,211,000	663,000
Computer hardware, furniture and fixtures
Property and Equipment
Property and equipment, gross	1,377,000	899,000
Leased assets
Property and Equipment
Property and equipment, gross	228,000	228,000
Leasehold improvements
Property and Equipment
Property and equipment, gross	$4,365,000	$4,260,000

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory
Total Biosurgery inventory, net	$10,924	$1,929
Biosurgery segment
Inventory
Raw materials and supplies	1,025	387
Work-in-process	465	22
Finished goods	9,434	1,520
Total Biosurgery inventory, net	$10,924	$1,929

Capital_Lease_Details

Capital Lease (Details) (USD $)	1 Months Ended
	Jul. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Capital Lease
Effective interest rate (as a percent)	5.00%
Term of lease	60 months
Amount of monthly payments of capital lease	$4,000
Future minimum lease payments under the capital lease agreement
2015		48,000
2016		48,000
2017		24,000
Total		120,000
Less: Amount representing interest		-3,000
Present value of minimum lease payments		117,000
Less: Current portion of capital lease obligations		-45,000	-45,000
Long-term portion of capital lease obligations		$72,000

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Assumptions to estimate the fair value of stock options granted
Proceeds for exercise of options	$1,685,000	$2,193,000	$87,000
Weighted Average Remaining Term Contractual Life
Outstanding at the beginning of the period				6 years 9 months 18 days
Outstanding at the end of the period				6 years 9 months 18 days
Aggregate Intrinsic Value
Exercised (in dollars)			114,000
Stock options
Share-Based Compensation
Vesting period	4 years
Contractual life	10 years
Assumptions to estimate the fair value of stock options granted
Dividend yield (as a percent)	0.00%	0.00%	0.00%
Expected life of option grants	5 years		6 years
Weighted average expected stock price volatility, minimum (as a percent)		52.00%	52.00%
Weighted average expected stock price volatility, maximum (as a percent)		61.00%
Weighted average expected stock price volatility	60.00%
Coupon rate on United States government issues used to determine risk-free interest rate (as a percent)	1.50%		2.00%
Proceeds for exercise of options	1,700,000
Total unrecognized compensation costs related to non-vested stock options	4,600,000
Number of Shares
Outstanding at the beginning of the period (in shares)	1,233,767	1,826,114	1,702,072
Granted (in shares)	988,500	452,000	302,000
Exercised (in shares)	-204,085	-642,514	-28,708
Forfeited or Canceled (in shares)	-409,625	-401,833	-149,250
Outstanding at the end of the period (in shares)	1,608,557	1,233,767	1,826,114
Exercisable at the end of the period (in shares)	400,432
Weighted Average Exercise Price Per Share
Outstanding at the beginning of the period (in dollars per share)	$10.61	$8.72	$9.06
Granted (in dollars per share)	$14.59	$9.03	$5.50
Exercised (in dollars per share)	($8.25)	($6.50)	($3.05)
Forfeited or canceled (in dollars per share)	($15.92)	($6.79)	($7.20)
Outstanding at the end of the period (in dollars per share)	$12.01	$10.61	$8.72
Exercisable at the end of the period (in dollars per share)	$9.79
Weighted Average Remaining Term Contractual Life
Outstanding at the beginning of the period	7 years 11 months 1 day	6 years 3 months 18 days	6 years 1 month 6 days
Outstanding at the end of the period	7 years 11 months 1 day	6 years 3 months 18 days	6 years 1 month 6 days
Exercisable at the end of the period	5 years 15 days
Aggregate Intrinsic Value
Outstanding at the beginning of the period (in dollars)	7,992,000	4,754,000
Exercised (in dollars)	1,341,000	6,983,000
Outstanding at the end of the period (in dollars)	6,774,000	7,992,000	4,754,000
Exercisable at the end of the period (in dollars)	$2,759,000
Weighted average fair value of options granted (in dollars per share)	$7.62	$4.68	$2.82
Stock options | Minimum
Assumptions to estimate the fair value of stock options granted
Expected life of option grants		5 years
Coupon rate on United States government issues used to determine risk-free interest rate (as a percent)		1.00%
Stock options | Maximum
Assumptions to estimate the fair value of stock options granted
Expected life of option grants		6 years 6 months	6 years 3 months 18 days
Weighted average expected stock price volatility, maximum (as a percent)			54.00%
Coupon rate on United States government issues used to determine risk-free interest rate (as a percent)		1.50%
Amended and Restated 2006 Omnibus Plan
Share-Based Compensation
Common stock reserved for issuance (in shares)	2,250,000
Shares available for future issuance	513,906
Amended and Restated 1994 Stock Incentive Plan
Share-Based Compensation
Common stock reserved for issuance (in shares)	736,378
Shares available for future issuance	0

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 2) (Stock options, USD $)	12 Months Ended
	Dec. 31, 2014
Options Outstanding
Number Outstanding (in shares)	1,608,557
Weighted Average Remaining Contractual Life	8 years
Weighted-Average Exercise Price (in dollars per share)	$12.01
Options Exercisable
Number Exercisable (in shares)	400,432
Weighted-Average Exercise Price (in dollars per share)	$9.79
$0.01 to $1.00
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$0.40
Exercise price, upper range limit (in dollars per share)	$4
Options Outstanding
Number Outstanding (in shares)	8,813
Weighted Average Remaining Contractual Life	10 months 24 days
Weighted-Average Exercise Price (in dollars per share)	$0.40
Options Exercisable
Number Exercisable (in shares)	8,813
Weighted-Average Exercise Price (in dollars per share)	$0.40
$1.01 to $5.00
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$4.01
Exercise price, upper range limit (in dollars per share)	$5.25
Options Outstanding
Number Outstanding (in shares)	133,790
Weighted Average Remaining Contractual Life	7 years 1 month 6 days
Weighted-Average Exercise Price (in dollars per share)	$5.31
Options Exercisable
Number Exercisable (in shares)	51,790
Weighted-Average Exercise Price (in dollars per share)	$5.08
$5.01 to $6.75
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$5.26
Exercise price, upper range limit (in dollars per share)	$7.25
Options Outstanding
Number Outstanding (in shares)	171,815
Weighted Average Remaining Contractual Life	5 years 4 months 24 days
Weighted-Average Exercise Price (in dollars per share)	$6.89
Options Exercisable
Number Exercisable (in shares)	121,065
Weighted-Average Exercise Price (in dollars per share)	$6.85
$6.76 to $7.50
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$7.01
Exercise price, upper range limit (in dollars per share)	$7.75
Options Outstanding
Number Outstanding (in shares)	210,139
Weighted Average Remaining Contractual Life	7 years 3 months 18 days
Weighted-Average Exercise Price (in dollars per share)	$7.73
Options Exercisable
Number Exercisable (in shares)	86,764
Weighted-Average Exercise Price (in dollars per share)	$7.74
$7.51 to $8.50
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$7.76
Exercise price, upper range limit (in dollars per share)	$8.50
Options Outstanding
Number Outstanding (in shares)	6,625
Weighted Average Remaining Contractual Life	7 years 10 months 24 days
Weighted-Average Exercise Price (in dollars per share)	$8.22
Options Exercisable
Number Exercisable (in shares)	750
Weighted-Average Exercise Price (in dollars per share)	$7.80
$8.51 to $12.25
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$8.51
Exercise price, upper range limit (in dollars per share)	$12.75
Options Outstanding
Number Outstanding (in shares)	151,375
Weighted Average Remaining Contractual Life	7 years 10 months 24 days
Weighted-Average Exercise Price (in dollars per share)	$11.42
Options Exercisable
Number Exercisable (in shares)	42,750
Weighted-Average Exercise Price (in dollars per share)	$11.23
$12.26 to $15.00
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$12.76
Exercise price, upper range limit (in dollars per share)	$14
Options Outstanding
Number Outstanding (in shares)	342,000
Weighted Average Remaining Contractual Life	9 years 4 months 24 days
Weighted-Average Exercise Price (in dollars per share)	$13.51
Options Exercisable
Number Exercisable (in shares)	8,250
Weighted-Average Exercise Price (in dollars per share)	$13
$15.01 to $17.50
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$14.01
Exercise price, upper range limit (in dollars per share)	$16
Options Outstanding
Number Outstanding (in shares)	290,000
Weighted Average Remaining Contractual Life	9 years 3 months 18 days
Weighted-Average Exercise Price (in dollars per share)	$15.01
$17.51 to $20.00
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$16.01
Exercise price, upper range limit (in dollars per share)	$17.50
Options Outstanding
Number Outstanding (in shares)	230,500
Weighted Average Remaining Contractual Life	8 years 8 months 12 days
Weighted-Average Exercise Price (in dollars per share)	$16.48
Options Exercisable
Number Exercisable (in shares)	16,750
Weighted-Average Exercise Price (in dollars per share)	$17.08
$ 20.01 to $23.62
Outstanding and exercisable options
Exercise price, lower range limit (in dollars per share)	$17.51
Exercise price, upper range limit (in dollars per share)	$24
Options Outstanding
Number Outstanding (in shares)	63,500
Weighted Average Remaining Contractual Life	3 years 7 months 6 days
Weighted-Average Exercise Price (in dollars per share)	$20.03
Options Exercisable
Number Exercisable (in shares)	63,500
Weighted-Average Exercise Price (in dollars per share)	$20.03

ShareBased_Compensation_Detail2

Share-Based Compensation (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based compensation expense
Discontinued operations		$658	$598
Stock options
Share-based compensation expense
Share-based compensation	3,132	1,241	1,090
Research and development | Stock options
Share-based compensation expense
Share-based compensation	1,802	335	238
Selling, general and administrative | Stock options
Share-based compensation expense
Share-based compensation	$1,330	$248	$254

Investments_Available_for_Sale2

Investments Available for Sale (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Investments available for sale
Cost	$37,359	$39,541
Unrealized Gain	47	36
Unrealized loss	-101	-69
Fair value of investments available for sale	37,305	39,508
Fair Value
Less than 12 Months	14,885	11,675
12 Months or more	1,032
Total	15,917	11,675
Unrealized Loss
Less than 12 Months	-55	-69
12 Months or more	-46
Total	-101	-69
Investments
Investments available for sale
Cost	23,481	32,531
Unrealized Gain	26	14
Unrealized loss	-77	-59
Fair value of investments available for sale	23,430	32,486
Municipal Securities
Investments available for sale
Cost	12,400	12,507
Unrealized Gain	13	9
Unrealized loss	-47	-24
Fair value of investments available for sale	12,366	12,492
Fair Value
Less than 12 Months	1,000	4,530
12 Months or more	1,032
Total	2,032	4,530
Unrealized Loss
Less than 12 Months	-1	-24
12 Months or more	-46
Total	-47	-24
Agency Obligations
Investments available for sale
Cost	5,401	6,704
Unrealized Gain	12	5
Unrealized loss	-28	-35
Fair value of investments available for sale	5,385	6,674
Fair Value
Less than 12 Months	3,939	3,804
Total	3,939	3,804
Unrealized Loss
Less than 12 Months	-28	-35
Total	-28	-35
Mutual Funds
Investments available for sale
Cost		4,076
Fair value of investments available for sale		4,076
US and International government agencies
Investments available for sale
Cost	5,680	9,244
Unrealized Gain	1
Unrealized loss	-2
Fair value of investments available for sale	5,679	9,244
Fair Value
Less than 12 Months	2,873
Total	2,873
Unrealized Loss
Less than 12 Months	-2
Total	-2
Cash equivalents
Investments available for sale
Cost	13,878	7,010
Unrealized Gain	21	22
Unrealized loss	-24	-10
Fair value of investments available for sale	13,875	7,022
Money market funds and certificates of deposit
Investments available for sale
Cost	1,043	655
Fair value of investments available for sale	1,043	655
Corporate debt securities & commercial paper
Investments available for sale
Cost	12,835	6,355
Unrealized Gain	21	22
Unrealized loss	-24	-10
Fair value of investments available for sale	12,832	6,367
Fair Value
Less than 12 Months	7,073	3,341
Total	7,073	3,341
Unrealized Loss
Less than 12 Months	-24	-10
Total	($24)	($10)

Investments_Available_for_Sale3

Investments Available for Sale (Details 2) - 10Q (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cost
Maturities Within 3-months	$3,056	$12,663
Maturities Between 3 - 12 months	12,658	1,624
More than 1 year	21,645	25,254
Cost of investments available for sale	37,359	39,541
Fair Value
Maturities Within 3-months	3,056	12,664
Maturities Between 3 - 12 months	12,660	1,610
More than 1 year	21,589	25,234
Fair value of investments available for sale	37,305	39,508
Realized gains and investment income earned on investments available for sale	($390)	($414)	$0

Related_Party_Transactions_and1

Related Party Transactions and Warrant (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 14, 2013
Related Party Transaction and Warrants
Value of shares issued to related party for servicing as Board of Director	$403,000	$180,000	$127,000
Warrant
Related Party Transaction and Warrants
Issuance of common stock on exercise of warrants (in shares)				567,610
Number of shares of common stock that can be purchased through outstanding warrant			1,000,000
Exercise price (in dollars per share)			$11
Chairman of Board of Directors
Related Party Transaction and Warrants
Debt and equity financing procured by related party	270,000,000
Percentage of beneficial ownership interest held by related party	43.00%
Number of shares received by related party as Board compensation since 1996	85,000
Shares granted in recognition of fundraising efforts by related party	12,500
Shares issued to related party for servicing as Board of Director	10,000	10,000	10,000
Value of shares issued to related party for servicing as Board of Director	$149,300	$77,000	$51,000
Direct ownership percentage held in entity by related party	29.30%
Chairman of Board of Directors | Prolexys Pharmaceuticals, Inc
Related Party Transaction and Warrants
Percentage of ownership interest held by related party in research agreement counterparty	24.30%
Percentage of ownership interest held by related party in another related party with ownership interest in research agreement counterparty	2.00%
Additional percentage of ownership interest in counterparty to agreement which will be acquired by related party upon conversion of convertible bond	19.00%
Chairman of Board of Directors | Warrant
Related Party Transaction and Warrants
Issuance of common stock on exercise of warrants (in shares)	567,610
Number of shares of common stock that can be purchased through outstanding warrant	1,000,000
Exercise price (in dollars per share)	$11
BIH SA
Related Party Transaction and Warrants
Ownership percentage held in entity by related party	7.80%
BIH SA | Prolexys Pharmaceuticals, Inc
Related Party Transaction and Warrants
Percentage of ownership interest held by related party in research agreement counterparty	35.70%
Venturetec, Inc
Related Party Transaction and Warrants
Ownership percentage held in entity by related party	12.50%
Venturetec, Inc | Prolexys Pharmaceuticals, Inc
Related Party Transaction and Warrants
Percentage of ownership interest held by related party in research agreement counterparty	13.80%

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes
Income tax expense	($193,000)	$1,326,000	$37,000
Income tax expense, which was offset against the income from discontinued operations	941,000	0	0
Income tax expense related to gain from sale of discontinued operation		1,705,000
Amount of taxes recoverable from a prior period included in tax benefits		79,000
Interest accrued included in gain from sale of discontinued operations		70,000
Effective tax rate varies from the U.S. Federal Statutory tax rate
U.S. Federal Statutory tax rate (as a percent)	35.00%	35.00%	35.00%
State taxes, net of federal benefits (as a percent)	-306.60%	7.00%	0.00%
Nondeductible expenses	-329.20%	-1.40%	-5.60%
Stock compensation	-2762.80%	12.10%
Change in valuation allowance (as a percent)	2116.50%		-29.40%
Other (as a percent)	-20.60%		0.60%
Change in tax rate	682.30%
Credit	228.10%	2.10%
Effective tax rate (as a percent)	-357.30%	54.80%	0.60%
Deferred Tax Assets:
Credits	70,219,000	76,023,000
Stock options - NQSO	594,000	1,689,000
Fixed assets	831,000	811,000
Accrued Expenses	301,000	101,000
Allowance for doubtful accounts	466,000	31,000
Deferred Rent	97,000
UNICAP	336,000
Other	1,000
Deferred tax assets gross	72,845,000	78,655,000
Valuation allowance	-72,701,000	-72,601,000
Net deferred tax assets	144,000	6,054,000
Deferred Tax Liabilities:
Gain on installment sale		6,054,000
Other	144,000
Net operating loss carryforwards	1,670,000
Amount of windfall stock compensation deductions	5,400,000
Accruals for interest or penalties related to income tax matters	$0	$0

Income_Taxes_Details_2

Income Taxes (Details 2) (General business credit carry-forwards, USD $)	Dec. 31, 2014
In Millions, unless otherwise specified
General business credit carry-forwards
Tax credit carryforwards
Tax credit amount	$70.50

Defined_Contribution_Plan_Deta

Defined Contribution Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Defined Contribution Plan
Vesting period	7 years
Eligibility period for commencement of vesting	3 years
Employer contributions to date	$0

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2012	Jul. 02, 2013	Jul. 01, 2011	Dec. 31, 2009	Dec. 31, 2006
								sqft
Contract Research Organizations
Estimated future CRO obligations	$10,700,000
Capital leases
Equipment under lease agreement				228,000
Accumulated depreciation of equipment acquired under capital lease	114,100
Columbia Facility
Operating lease
Area of property leased (in square feet)								61,000
Letter of credit outstanding in lieu of security deposit	9						243,000
Security deposit required under lease agreement					95,000	243,000
Allowance from the landlord for tenant improvements	1,500,000
Future minimum lease payments due under the operating lease
2015	1,194,000
2016	1,091,000
2017	1,062,000
2018	1,088,000
2019	1,218,000
Thereafter	4,957,000
Future minimum lease payments due	10,610,000
Lease expenses	$1,300,000	$1,300,000	$1,300,000

Derivative_and_Securities_Rece1

Derivative and Securities Received in Business Disposition (Details) (USD $)	0 Months Ended			12 Months Ended	3 Months Ended
	Dec. 31, 2013	Oct. 10, 2013	Oct. 10, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 18, 2013
Derivative instruments
Other receivables	$15,265,000			$9,951,000	$15,265,000
Purchase Agreement with Mesoblast
Derivative instruments
Initial consideration payable either in cash or ordinary shares			15,000,000
Holding period for any payments made in ordinary shares		1 year
Aggregate compensation to be received for decrease in value of shares (as a percent)				50.00%
Aggregate compensation to be received for decrease in value of shares payable in cash (as a percent)				50.00%
Aggregate compensation to be received for decrease in value of shares payable in cash or ordinary shares (as a percent)				100.00%
Holding period of stock subject to limited price protection	1 year
Gain loss from shares received from discontinued operations	401,000			401,000
Other receivables				4,400,000
Purchase Agreement with Mesoblast | Therapeutics segment
Derivative instruments
Holding period for any payments made in ordinary shares		1 year
Fair value of the shares received from discontinued operations						15,000,000
Other receivables				4,400,000
Purchase Agreement with Mesoblast | Hedging instrument
Derivative instruments
Fair value of derivative instruments				1,700,000
Purchase Agreement with Mesoblast | Hedging instrument | Therapeutics segment
Derivative instruments
Loss on derivative instruments					$52,000
Holding period of stock subject to limited price protection	1 year

Fair_Value_Details

Fair Value (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value
Transfers between level 1 and level 2	$0
Transfers between level 2 and level 1	0
Rollforward of the fair value of Level 3 instruments
Balance at beginning of period	1,685,000
Fair value upon receipt of Mesoblast stock		1,737,000
Change in Fair Value	2,252,000	-52,000
Expiration of the price protection derivative	-3,937,000
Balance at end of period		1,685,000
Recurring | Price Protection On Restricted Shares Of Mesoblast Common Stock | Level III
Significant inputs
Fair value	$15,000,000
Contractual life	1 year
Volatility (as a percent)	40.00%
Risk free interest rate (as a percent)	0.13%
Expected dividends	$0

Fair_Value_Details_2

Fair Value (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Assets
Investments available for sale	$37,305,000	$39,508,000
Recurring | Level I
Assets
Investments available for sale	1,043,000	655,000
Derivative and securities received in business disposition	10,591,000	15,401,000
Total assets	11,634,000	16,056,000
Recurring | Level II
Assets
Investments available for sale	36,262,000	38,853,000
Total assets	36,262,000	38,853,000
Recurring | Level III
Assets
Derivative and securities received in business disposition		1,685,000
Total assets		1,685,000
Recurring | Total
Assets
Investments available for sale	37,305,000	39,508,000
Derivative and securities received in business disposition	10,591,000	17,086,000
Total assets	47,896,000	56,594,000
Recurring | Cash equivalents | Level I
Assets
Investments available for sale	1,043,000	655,000
Recurring | Cash equivalents | Total
Assets
Investments available for sale	1,043,000	655,000
Recurring | Government Obligations | Level II
Assets
Investments available for sale	5,679,000	9,244,000
Recurring | Government Obligations | Total
Assets
Investments available for sale	5,679,000	9,244,000
Recurring | Mutual Funds | Level II
Assets
Investments available for sale		4,076,000
Recurring | Mutual Funds | Total
Assets
Investments available for sale		4,076,000
Recurring | Agency Obligations | Level II
Assets
Investments available for sale	5,385,000	6,674,000
Recurring | Agency Obligations | Total
Assets
Investments available for sale	5,385,000	6,674,000
Recurring | Corporate debt securities & commercial paper | Level II
Assets
Investments available for sale	12,832,000	6,367,000
Recurring | Corporate debt securities & commercial paper | Total
Assets
Investments available for sale	12,832,000	6,367,000
Recurring | Municipal Securities | Level II
Assets
Investments available for sale	12,366,000	12,492,000
Recurring | Municipal Securities | Total
Assets
Investments available for sale	12,366,000	12,492,000
Recurring | Restricted shares of Mesoblast common stock | Level I
Assets
Derivative and securities received in business disposition		15,401,000
Fair value of securities	10,591,000
Recurring | Restricted shares of Mesoblast common stock | Total
Assets
Derivative and securities received in business disposition		15,401,000
Fair value of securities	10,591,000
Recurring | Price Protection On Restricted Shares Of Mesoblast Common Stock | Level III
Assets
Derivative and securities received in business disposition		1,685,000
Derivative instruments	15,000,000
Recurring | Price Protection On Restricted Shares Of Mesoblast Common Stock | Total
Assets
Derivative and securities received in business disposition		$1,685,000

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Data (Unaudited)
Product revenues	$19,319	$17,204	$13,290	$10,054	$8,080	$6,882	$5,291	$4,055
Gross profit	15,069	13,419	10,366	7,842	5,898	5,024	3,810	2,920	46,696	17,652	5,298
Research and development expenses	3,930	1,207	1,055	670	1,950	913	1,132	957	6,862	4,952	5,501
Selling General and administrative expenses and fees	9,959	10,993	9,377	7,787	4,128	4,602	4,157	2,646
Loss from continuing operations	1,083	710	-1,428	-611	1,481	-466	-1,454	-654	-246	-1,093	-5,747
Loss from discontinued operations	-267	-65	-457	-754	48,325	-1,211	-2,302	-2,081	-1,543	42,731	-5,318
Net (loss) income	$816	$645	($1,885)	($1,365)	$49,806	($1,677)	($3,756)	($2,735)	($1,789)	$41,638	($11,065)
Loss from continuing operations per share, basic and diluted (in dollars per share)	$0.03	$0.02	($0.04)	($0.02)	$0.03	($0.01)	($0.04)	($0.02)	($0.01)	($0.04)	($0.17)
(Loss) income from discontinued operations per share, basic (in dollars per share)					$1.43	($0.04)	($0.07)	($0.06)
(Loss) income from discontinued operations per share, diluted (in dollars per share)					$1.46	($0.04)	($0.07)	($0.06)
Income (Loss) from discontinued operations per shares, basic and diluted (in dollars per share)	($0.01)	$0	($0.01)	($0.02)					($0.04)	$1.29	($0.16)
Net loss per share, diluted (in dollars per share)					$1.49	($0.05)	($0.11)	($0.08)
Net loss per share, basic (in dollars per share)					$1.46	($0.05)	($0.11)	($0.08)
Basic and diluted income (loss) per share (in dollars per share)	$0.02	$0.02	($0.05)	($0.04)					($0.05)	$1.25	($0.33)

Subsequent_Event_Details

Subsequent Event (Details) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Dec. 31, 2014
		item
Subsequent Events
Exclusivity fee	$5
Number Of Business Days Of Receipt Of Documents		5

SCHEDULE_IIVALUATION_AND_QUALI1

SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts Receivable Reserve:
Valuation and qualifying accounts
Balance at Beginning of Year	$78	$25	$3
Additions	1,178	80	22
Deductions		-27
Balance at End of Year	1,256	78	25
Inventory Reserve:
Valuation and qualifying accounts
Balance at Beginning of Year		112	274
Deductions		-112	-162
Balance at End of Year			112
Net Deferred Tax Asset Valuation Allowance:
Valuation and qualifying accounts
Balance at Beginning of Year	72,601	88,243	84,134
Additions	100		4,109
Deductions		-15,642
Balance at End of Year	$72,701	$72,601	$88,243